PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
26809192-0	2016	Xanthotoxin prevents bone loss in ovariectomized mice through the inhibition of RANKL-induced osteoclastogenesis.	Methoxsalen	0-11	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	80-85
27427773-5	2016	Interestingly, however, another commonly used PARP inhibitor PJ-34 proved to be a photosensitizer with potency equal to 8-MOP.	Methoxsalen	120-125	poly(ADP-ribose) polymerase 1	Homo sapiens	46-50
26808085-0	2016	The anti-metastatic effect of 8-MOP on hepatocellular carcinoma is potentiated by the down-regulation of bHLH transcription factor DEC1.	Methoxsalen	30-35	deleted in esophageal cancer 1	Homo sapiens	131-135
26808085-3	2016	In this study, it was demonstrated that 8-MOP inhibited HCC HepG2 cells and SMMC-7721 cells migratory and invasive potentiality, as well as modulated the expression of various EMT-associated genes such as enhancing E-cadherin and reducing N-cadherin, vimentin, alpha-SMA and MMP9 in a concentration-dependent way.	Methoxsalen	40-45	IL2 inducible T cell kinase	Homo sapiens	176-179
26808085-3	2016	In this study, it was demonstrated that 8-MOP inhibited HCC HepG2 cells and SMMC-7721 cells migratory and invasive potentiality, as well as modulated the expression of various EMT-associated genes such as enhancing E-cadherin and reducing N-cadherin, vimentin, alpha-SMA and MMP9 in a concentration-dependent way.	Methoxsalen	40-45	cadherin 1	Homo sapiens	215-225
26808085-3	2016	In this study, it was demonstrated that 8-MOP inhibited HCC HepG2 cells and SMMC-7721 cells migratory and invasive potentiality, as well as modulated the expression of various EMT-associated genes such as enhancing E-cadherin and reducing N-cadherin, vimentin, alpha-SMA and MMP9 in a concentration-dependent way.	Methoxsalen	40-45	cadherin 2	Homo sapiens	239-249
26808085-3	2016	In this study, it was demonstrated that 8-MOP inhibited HCC HepG2 cells and SMMC-7721 cells migratory and invasive potentiality, as well as modulated the expression of various EMT-associated genes such as enhancing E-cadherin and reducing N-cadherin, vimentin, alpha-SMA and MMP9 in a concentration-dependent way.	Methoxsalen	40-45	vimentin	Homo sapiens	251-259
26808085-3	2016	In this study, it was demonstrated that 8-MOP inhibited HCC HepG2 cells and SMMC-7721 cells migratory and invasive potentiality, as well as modulated the expression of various EMT-associated genes such as enhancing E-cadherin and reducing N-cadherin, vimentin, alpha-SMA and MMP9 in a concentration-dependent way.	Methoxsalen	40-45	matrix metallopeptidase 9	Homo sapiens	275-279
26808085-5	2016	8-MOP suppressed the expression of DEC1 in a concentration- and time-dependent manner.	Methoxsalen	0-5	deleted in esophageal cancer 1	Homo sapiens	35-39
26808085-6	2016	Overexpression of DEC1 endorsed the HepG2 cells a higher metastatic phenotype, while totally abolished 8-MOP-repressed metastatic capability.	Methoxsalen	103-108	deleted in esophageal cancer 1	Homo sapiens	18-22
26808085-8	2016	In vivo experiments revealed that the treatment of 8-MOP (5 or 20mg/kg) resulted in a dose-dependent decreases in the lung metastasis of hepatoma H22-transplanted mice without any obvious toxicity to the organs, as well as increased expression of E-cadherin in lung tissues.	Methoxsalen	51-56	cadherin 1	Mus musculus	247-257
26808085-9	2016	Consistently, 8-MOP down-regulated the expression of DEC1 in the lungs of tumor-bearing mice, which further confirms that DEC1 was correlated with 8-MOP-induced anti-metastatic effect.	Methoxsalen	14-19	basic helix-loop-helix family, member e40	Mus musculus	53-57
26808085-9	2016	Consistently, 8-MOP down-regulated the expression of DEC1 in the lungs of tumor-bearing mice, which further confirms that DEC1 was correlated with 8-MOP-induced anti-metastatic effect.	Methoxsalen	14-19	basic helix-loop-helix family, member e40	Mus musculus	122-126
26808085-9	2016	Consistently, 8-MOP down-regulated the expression of DEC1 in the lungs of tumor-bearing mice, which further confirms that DEC1 was correlated with 8-MOP-induced anti-metastatic effect.	Methoxsalen	147-152	basic helix-loop-helix family, member e40	Mus musculus	53-57
26808085-9	2016	Consistently, 8-MOP down-regulated the expression of DEC1 in the lungs of tumor-bearing mice, which further confirms that DEC1 was correlated with 8-MOP-induced anti-metastatic effect.	Methoxsalen	147-152	basic helix-loop-helix family, member e40	Mus musculus	122-126
26808085-10	2016	The present findings establish a function for DEC1 in HCC metastatic progression and suggest its candidacy as a novel target for the anti-metastasis effect of 8-MOP.	Methoxsalen	159-164	deleted in esophageal cancer 1	Homo sapiens	46-50
26051797-2	2015	ECP should be validated: we compared in parallel apoptosis and proliferation analysis of patient lymphocytes treated with 8-MOP ECP using respectively Annexin V/7-aminoactinomycin D (7-AAD) and CFSE with a tetrazolium salt (WST-1) method.	Methoxsalen	122-127	annexin A5	Homo sapiens	151-160
25498103-0	2014	Infusion of dendritic cells carrying donor lymphocytes treated with 8-methoxypsoralen and ultraviolet A light induces CD19+ IL-10+ regulatory B cells and promotes skin allograft survival.	Methoxsalen	68-85	CD19 molecule	Homo sapiens	118-122
26316083-0	2015	8-Methoxypsoralen Induces Intrinsic Apoptosis in HepG2 Cells: Involvement of Reactive Oxygen Species Generation and ERK1/2 Pathway Inhibition.	Methoxsalen	0-17	mitogen-activated protein kinase 3	Homo sapiens	116-122
26316083-8	2015	In addition, the activation of ERK1/2 was drastically decreased by 8-MOP as ERK inhibitor PD98059, indicating a role of ERK1/2 signaling pathway in 8-MOP-induced cell apoptosis.	Methoxsalen	67-72	mitogen-activated protein kinase 3	Homo sapiens	31-37
26316083-8	2015	In addition, the activation of ERK1/2 was drastically decreased by 8-MOP as ERK inhibitor PD98059, indicating a role of ERK1/2 signaling pathway in 8-MOP-induced cell apoptosis.	Methoxsalen	67-72	mitogen-activated protein kinase 1	Homo sapiens	31-34
26316083-8	2015	In addition, the activation of ERK1/2 was drastically decreased by 8-MOP as ERK inhibitor PD98059, indicating a role of ERK1/2 signaling pathway in 8-MOP-induced cell apoptosis.	Methoxsalen	67-72	mitogen-activated protein kinase 3	Homo sapiens	120-126
26316083-8	2015	In addition, the activation of ERK1/2 was drastically decreased by 8-MOP as ERK inhibitor PD98059, indicating a role of ERK1/2 signaling pathway in 8-MOP-induced cell apoptosis.	Methoxsalen	148-153	mitogen-activated protein kinase 3	Homo sapiens	31-37
26316083-8	2015	In addition, the activation of ERK1/2 was drastically decreased by 8-MOP as ERK inhibitor PD98059, indicating a role of ERK1/2 signaling pathway in 8-MOP-induced cell apoptosis.	Methoxsalen	148-153	mitogen-activated protein kinase 1	Homo sapiens	31-34
26316083-8	2015	In addition, the activation of ERK1/2 was drastically decreased by 8-MOP as ERK inhibitor PD98059, indicating a role of ERK1/2 signaling pathway in 8-MOP-induced cell apoptosis.	Methoxsalen	148-153	mitogen-activated protein kinase 3	Homo sapiens	120-126
26316083-9	2015	CONCLUSION: 8-MOP induces intrinsic apoptosis by increasing ROS generation and inhibiting ERK1/2 pathway in HepG2 cells.	Methoxsalen	12-17	mitogen-activated protein kinase 3	Homo sapiens	90-96
26210672-5	2015	The catalytic property of cytochrome P450 2A5 (CYP2A5) enzyme in mice was determined by the coumarin 7-hydroxylation reaction, suggesting that 8-MOP produced remarkable inhibition on CYP2A5 in female C57BL/6 mice.	Methoxsalen	143-148	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	26-45
26210672-5	2015	The catalytic property of cytochrome P450 2A5 (CYP2A5) enzyme in mice was determined by the coumarin 7-hydroxylation reaction, suggesting that 8-MOP produced remarkable inhibition on CYP2A5 in female C57BL/6 mice.	Methoxsalen	143-148	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	47-53
26210672-5	2015	The catalytic property of cytochrome P450 2A5 (CYP2A5) enzyme in mice was determined by the coumarin 7-hydroxylation reaction, suggesting that 8-MOP produced remarkable inhibition on CYP2A5 in female C57BL/6 mice.	Methoxsalen	143-148	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	183-189
26210672-6	2015	These results implied that 8-MOP could prevent NNK-induced mutagenesis and tumorigenesis in mice through the inhibition of NNK alpha-hydroxylation, which may be achieved through the effect of 8-MOP on the bioactivities of CYP2A5.	Methoxsalen	27-32	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	222-228
26210672-6	2015	These results implied that 8-MOP could prevent NNK-induced mutagenesis and tumorigenesis in mice through the inhibition of NNK alpha-hydroxylation, which may be achieved through the effect of 8-MOP on the bioactivities of CYP2A5.	Methoxsalen	192-197	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	222-228
25498103-0	2014	Infusion of dendritic cells carrying donor lymphocytes treated with 8-methoxypsoralen and ultraviolet A light induces CD19+ IL-10+ regulatory B cells and promotes skin allograft survival.	Methoxsalen	68-85	interleukin 10	Homo sapiens	124-129
24215840-0	2014	Activation of GILZ gene by photoactivated 8-methoxypsoralen: potential role of immunoregulatory dendritic cells in extracorporeal photochemotherapy.	Methoxsalen	42-59	TSC22 domain family member 3	Homo sapiens	14-18
24610393-4	2014	Herein, we studied the change in miRNA profiles of cultured human keratinocytes (HaCaT cells) before and after in vitro PUVA treatment by 8 methoxypsoralen and found significant up regulation of hsa-miR-4516.	Methoxsalen	138-155	microRNA 4516	Homo sapiens	199-207
24859605-0	2014	Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice.	Methoxsalen	11-22	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	26-32
24859605-2	2014	We therefore hypothesized that inhibition of mouse CYP2A5, the ortolog of human CYP2A6, by methoxsalen (8-methoxypsoralen) alter dependence-related behaviors of nicotine in the mouse.	Methoxsalen	91-102	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	51-57
24859605-2	2014	We therefore hypothesized that inhibition of mouse CYP2A5, the ortolog of human CYP2A6, by methoxsalen (8-methoxypsoralen) alter dependence-related behaviors of nicotine in the mouse.	Methoxsalen	91-102	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	80-86
24859605-2	2014	We therefore hypothesized that inhibition of mouse CYP2A5, the ortolog of human CYP2A6, by methoxsalen (8-methoxypsoralen) alter dependence-related behaviors of nicotine in the mouse.	Methoxsalen	104-121	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	51-57
24859605-2	2014	We therefore hypothesized that inhibition of mouse CYP2A5, the ortolog of human CYP2A6, by methoxsalen (8-methoxypsoralen) alter dependence-related behaviors of nicotine in the mouse.	Methoxsalen	104-121	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	80-86
25324722-0	2014	8-Methoxypsoralen is a competitive inhibitor of glutathione S-transferase P1-1.	Methoxsalen	0-17	S100 calcium binding protein A10	Homo sapiens	74-78
25324722-6	2014	This study characterized 8-methoxypsoralen (8-MOP) as a human GST P1-1 (hGST P1-1) inhibitor.	Methoxsalen	25-42	glutathione S-transferase pi 1	Homo sapiens	62-70
25324722-6	2014	This study characterized 8-methoxypsoralen (8-MOP) as a human GST P1-1 (hGST P1-1) inhibitor.	Methoxsalen	25-42	S100 calcium binding protein A10	Homo sapiens	66-70
25324722-6	2014	This study characterized 8-methoxypsoralen (8-MOP) as a human GST P1-1 (hGST P1-1) inhibitor.	Methoxsalen	44-49	glutathione S-transferase pi 1	Homo sapiens	62-70
25324722-6	2014	This study characterized 8-methoxypsoralen (8-MOP) as a human GST P1-1 (hGST P1-1) inhibitor.	Methoxsalen	44-49	S100 calcium binding protein A10	Homo sapiens	66-70
25324722-7	2014	To identify and characterize the potential inhibitory activity of 8-MOP, we studied the enzyme kinetics of the conjugation of 1-chloro-2,4-dinitrobenzene (CDNB) with GSH catalyzed by hGST P1-1.	Methoxsalen	66-71	glutathione S-transferase pi 1	Homo sapiens	183-192
25324722-8	2014	We report here that 8-MOP competitively inhibited hGST P1-1 relative to CDNB, but there was an uncompetitive inhibition relative to GSH.	Methoxsalen	20-25	glutathione S-transferase pi 1	Homo sapiens	50-59
24086543-0	2013	Cytochrome P450 CYP1B1 interacts with 8-methoxypsoralen (8-MOP) and influences psoralen-ultraviolet A (PUVA) sensitivity.	Methoxsalen	38-55	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	16-22
24551203-5	2014	Using a mass spectroscopy-based approach, we show for the first time that photo-activated 8MOP (8-methoxypsoralen) interacts with the ErbB2 catalytic autokinase domain.	Methoxsalen	96-113	erb-b2 receptor tyrosine kinase 2	Homo sapiens	134-139
24475091-0	2014	Inhibitory potency of 8-methoxypsoralen on cytochrome P450 2A6 (CYP2A6) allelic variants CYP2A6 15, CYP2A6 16, CYP2A6 21 and CYP2A6 22: differential susceptibility due to different sequence locations of the mutations.	Methoxsalen	22-39	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	43-62
24475091-0	2014	Inhibitory potency of 8-methoxypsoralen on cytochrome P450 2A6 (CYP2A6) allelic variants CYP2A6 15, CYP2A6 16, CYP2A6 21 and CYP2A6 22: differential susceptibility due to different sequence locations of the mutations.	Methoxsalen	22-39	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	64-70
24475091-0	2014	Inhibitory potency of 8-methoxypsoralen on cytochrome P450 2A6 (CYP2A6) allelic variants CYP2A6 15, CYP2A6 16, CYP2A6 21 and CYP2A6 22: differential susceptibility due to different sequence locations of the mutations.	Methoxsalen	22-39	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	89-95
24475091-0	2014	Inhibitory potency of 8-methoxypsoralen on cytochrome P450 2A6 (CYP2A6) allelic variants CYP2A6 15, CYP2A6 16, CYP2A6 21 and CYP2A6 22: differential susceptibility due to different sequence locations of the mutations.	Methoxsalen	22-39	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	89-95
24475091-0	2014	Inhibitory potency of 8-methoxypsoralen on cytochrome P450 2A6 (CYP2A6) allelic variants CYP2A6 15, CYP2A6 16, CYP2A6 21 and CYP2A6 22: differential susceptibility due to different sequence locations of the mutations.	Methoxsalen	22-39	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	89-95
24475091-0	2014	Inhibitory potency of 8-methoxypsoralen on cytochrome P450 2A6 (CYP2A6) allelic variants CYP2A6 15, CYP2A6 16, CYP2A6 21 and CYP2A6 22: differential susceptibility due to different sequence locations of the mutations.	Methoxsalen	22-39	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	89-95
24475091-3	2014	In the present study, we further explored the ability of a typical CYP2A6 inhibitor, 8-methoxypsoralen (8-MOP), in inhibition of these alleles and we hypothesized that translational mutations in these variants are likely to give impact on 8-MOP inhibitory potency.	Methoxsalen	85-102	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	67-73
24475091-3	2014	In the present study, we further explored the ability of a typical CYP2A6 inhibitor, 8-methoxypsoralen (8-MOP), in inhibition of these alleles and we hypothesized that translational mutations in these variants are likely to give impact on 8-MOP inhibitory potency.	Methoxsalen	104-109	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	67-73
24475091-3	2014	In the present study, we further explored the ability of a typical CYP2A6 inhibitor, 8-methoxypsoralen (8-MOP), in inhibition of these alleles and we hypothesized that translational mutations in these variants are likely to give impact on 8-MOP inhibitory potency.	Methoxsalen	239-244	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	67-73
23884323-2	2014	METHODS: Studies were undertaken to examine whether the systemic administration of methoxsalen, an inhibitor of human CYP2A6 and mouse CYP2A5, would modulate nicotine pharmacokinetics and pharmacological effects (antinociception in the tail-flick, and hot-plate tests, and hypothermia) in male ICR mouse after acute oral nicotine administration.	Methoxsalen	83-94	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	118-124
23884323-2	2014	METHODS: Studies were undertaken to examine whether the systemic administration of methoxsalen, an inhibitor of human CYP2A6 and mouse CYP2A5, would modulate nicotine pharmacokinetics and pharmacological effects (antinociception in the tail-flick, and hot-plate tests, and hypothermia) in male ICR mouse after acute oral nicotine administration.	Methoxsalen	83-94	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	135-141
24086543-0	2013	Cytochrome P450 CYP1B1 interacts with 8-methoxypsoralen (8-MOP) and influences psoralen-ultraviolet A (PUVA) sensitivity.	Methoxsalen	57-62	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	16-22
24086543-6	2013	RESULTS: We showed that P450s CYP1A1, CYP1A2, CYP1B1, CYP2A6 and CYP2E1 influence 8-MOP metabolism.	Methoxsalen	82-87	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	30-36
24086543-6	2013	RESULTS: We showed that P450s CYP1A1, CYP1A2, CYP1B1, CYP2A6 and CYP2E1 influence 8-MOP metabolism.	Methoxsalen	82-87	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	38-44
24086543-6	2013	RESULTS: We showed that P450s CYP1A1, CYP1A2, CYP1B1, CYP2A6 and CYP2E1 influence 8-MOP metabolism.	Methoxsalen	82-87	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	46-52
24086543-6	2013	RESULTS: We showed that P450s CYP1A1, CYP1A2, CYP1B1, CYP2A6 and CYP2E1 influence 8-MOP metabolism.	Methoxsalen	82-87	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	54-60
24086543-6	2013	RESULTS: We showed that P450s CYP1A1, CYP1A2, CYP1B1, CYP2A6 and CYP2E1 influence 8-MOP metabolism.	Methoxsalen	82-87	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	65-71
24086543-7	2013	As CYP1B1 is the most abundant P450 in human skin, we further demonstrated that: (i) CYP1B1 interacts with 8-MOP (ii) metabolism of the CYP1B1 substrates 7-ethoxyresorufin and 17-beta-estradiol showed concentration-dependent inhibition by 8-MOP and (iii) inhibition of 7-ethoxyresorufin metabolism by 8-MOP was influenced by CYP1B1 genotype.	Methoxsalen	107-112	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	3-9
24086543-7	2013	As CYP1B1 is the most abundant P450 in human skin, we further demonstrated that: (i) CYP1B1 interacts with 8-MOP (ii) metabolism of the CYP1B1 substrates 7-ethoxyresorufin and 17-beta-estradiol showed concentration-dependent inhibition by 8-MOP and (iii) inhibition of 7-ethoxyresorufin metabolism by 8-MOP was influenced by CYP1B1 genotype.	Methoxsalen	107-112	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	85-91
24086543-7	2013	As CYP1B1 is the most abundant P450 in human skin, we further demonstrated that: (i) CYP1B1 interacts with 8-MOP (ii) metabolism of the CYP1B1 substrates 7-ethoxyresorufin and 17-beta-estradiol showed concentration-dependent inhibition by 8-MOP and (iii) inhibition of 7-ethoxyresorufin metabolism by 8-MOP was influenced by CYP1B1 genotype.	Methoxsalen	107-112	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	85-91
24086543-7	2013	As CYP1B1 is the most abundant P450 in human skin, we further demonstrated that: (i) CYP1B1 interacts with 8-MOP (ii) metabolism of the CYP1B1 substrates 7-ethoxyresorufin and 17-beta-estradiol showed concentration-dependent inhibition by 8-MOP and (iii) inhibition of 7-ethoxyresorufin metabolism by 8-MOP was influenced by CYP1B1 genotype.	Methoxsalen	107-112	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	85-91
24086543-7	2013	As CYP1B1 is the most abundant P450 in human skin, we further demonstrated that: (i) CYP1B1 interacts with 8-MOP (ii) metabolism of the CYP1B1 substrates 7-ethoxyresorufin and 17-beta-estradiol showed concentration-dependent inhibition by 8-MOP and (iii) inhibition of 7-ethoxyresorufin metabolism by 8-MOP was influenced by CYP1B1 genotype.	Methoxsalen	239-244	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	3-9
24086543-7	2013	As CYP1B1 is the most abundant P450 in human skin, we further demonstrated that: (i) CYP1B1 interacts with 8-MOP (ii) metabolism of the CYP1B1 substrates 7-ethoxyresorufin and 17-beta-estradiol showed concentration-dependent inhibition by 8-MOP and (iii) inhibition of 7-ethoxyresorufin metabolism by 8-MOP was influenced by CYP1B1 genotype.	Methoxsalen	239-244	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	85-91
24086543-7	2013	As CYP1B1 is the most abundant P450 in human skin, we further demonstrated that: (i) CYP1B1 interacts with 8-MOP (ii) metabolism of the CYP1B1 substrates 7-ethoxyresorufin and 17-beta-estradiol showed concentration-dependent inhibition by 8-MOP and (iii) inhibition of 7-ethoxyresorufin metabolism by 8-MOP was influenced by CYP1B1 genotype.	Methoxsalen	239-244	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	85-91
24086543-7	2013	As CYP1B1 is the most abundant P450 in human skin, we further demonstrated that: (i) CYP1B1 interacts with 8-MOP (ii) metabolism of the CYP1B1 substrates 7-ethoxyresorufin and 17-beta-estradiol showed concentration-dependent inhibition by 8-MOP and (iii) inhibition of 7-ethoxyresorufin metabolism by 8-MOP was influenced by CYP1B1 genotype.	Methoxsalen	239-244	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	85-91
24086543-7	2013	As CYP1B1 is the most abundant P450 in human skin, we further demonstrated that: (i) CYP1B1 interacts with 8-MOP (ii) metabolism of the CYP1B1 substrates 7-ethoxyresorufin and 17-beta-estradiol showed concentration-dependent inhibition by 8-MOP and (iii) inhibition of 7-ethoxyresorufin metabolism by 8-MOP was influenced by CYP1B1 genotype.	Methoxsalen	239-244	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	3-9
24086543-7	2013	As CYP1B1 is the most abundant P450 in human skin, we further demonstrated that: (i) CYP1B1 interacts with 8-MOP (ii) metabolism of the CYP1B1 substrates 7-ethoxyresorufin and 17-beta-estradiol showed concentration-dependent inhibition by 8-MOP and (iii) inhibition of 7-ethoxyresorufin metabolism by 8-MOP was influenced by CYP1B1 genotype.	Methoxsalen	239-244	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	85-91
24086543-7	2013	As CYP1B1 is the most abundant P450 in human skin, we further demonstrated that: (i) CYP1B1 interacts with 8-MOP (ii) metabolism of the CYP1B1 substrates 7-ethoxyresorufin and 17-beta-estradiol showed concentration-dependent inhibition by 8-MOP and (iii) inhibition of 7-ethoxyresorufin metabolism by 8-MOP was influenced by CYP1B1 genotype.	Methoxsalen	239-244	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	85-91
24086543-7	2013	As CYP1B1 is the most abundant P450 in human skin, we further demonstrated that: (i) CYP1B1 interacts with 8-MOP (ii) metabolism of the CYP1B1 substrates 7-ethoxyresorufin and 17-beta-estradiol showed concentration-dependent inhibition by 8-MOP and (iii) inhibition of 7-ethoxyresorufin metabolism by 8-MOP was influenced by CYP1B1 genotype.	Methoxsalen	239-244	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	85-91
22262919-9	2012	It is noteworthy that the remaining NNK bioactivation activities in the Cyp2a5-null mice could be inhibited by 8-methoxypsoralen, a P450 inhibitor used previously to demonstrate the role of CYP2A5 in NNK-induced lung tumorigenesis.	Methoxsalen	111-128	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	72-78
22796345-10	2012	And overexpression of DEC1 abolished the decrease of survivin and the activation of caspase-3 induced by 8-MOP partially.	Methoxsalen	105-110	caspase 3	Homo sapiens	84-93
22743290-9	2012	Finally, treatment with nicotine, a competitor of AFB(1), and 8-methoxypsoralen (8-MOP), an inhibitor of CYP enzyme, further confirm the critical role of CYP2A13 in AFB(1)-induced cytotoxicity and apoptosis.	Methoxsalen	62-79	cytochrome P450 family 2 subfamily A member 13	Homo sapiens	154-161
22743290-9	2012	Finally, treatment with nicotine, a competitor of AFB(1), and 8-methoxypsoralen (8-MOP), an inhibitor of CYP enzyme, further confirm the critical role of CYP2A13 in AFB(1)-induced cytotoxicity and apoptosis.	Methoxsalen	81-86	cytochrome P450 family 2 subfamily A member 13	Homo sapiens	154-161
23907605-7	2013	All the above effects were inhibited by nicotine (a substrate of CYP2A13) or 8-MOP (an inhibitor of CYP enzymes), confirming that CYP2A13 mediated the AFG1-induced cytotoxicity and DNA damages.	Methoxsalen	77-82	cytochrome P450 family 2 subfamily A member 13	Homo sapiens	130-137
23907605-7	2013	All the above effects were inhibited by nicotine (a substrate of CYP2A13) or 8-MOP (an inhibitor of CYP enzymes), confirming that CYP2A13 mediated the AFG1-induced cytotoxicity and DNA damages.	Methoxsalen	77-82	AFG1 like ATPase	Homo sapiens	151-155
23291118-2	2013	The 8-MOP analogs 19 and 24, incorporating at position 5 of the psoralen nucleus a butyl acrylate or a tert-butyl cinnamate moiety, were the most powerful inhibitors of soybean LOX and inhibited effectively lipid peroxidation.	Methoxsalen	4-9	seed linoleate 9S-lipoxygenase-3	Glycine max	177-180
22696418-8	2012	However, 8-methoxypsoralen has a 6-fold lower K(i) for CYP2A13 than for CYP2A6.	Methoxsalen	9-26	cytochrome P450 family 2 subfamily A member 13	Homo sapiens	55-62
22696418-8	2012	However, 8-methoxypsoralen has a 6-fold lower K(i) for CYP2A13 than for CYP2A6.	Methoxsalen	9-26	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	72-78
22350182-1	2012	This study was aimed to investigate the protective effects of ginsenoside Rg1 on 8-methoxypsoralen(8-MOP)/Ultraviolet A (UVA)-induced premature senescence in human fibroblasts, and the underlying mechanism.	Methoxsalen	81-98	protein phosphatase 1 regulatory subunit 3A	Homo sapiens	74-77
22262919-9	2012	It is noteworthy that the remaining NNK bioactivation activities in the Cyp2a5-null mice could be inhibited by 8-methoxypsoralen, a P450 inhibitor used previously to demonstrate the role of CYP2A5 in NNK-induced lung tumorigenesis.	Methoxsalen	111-128	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	190-196
22379972-0	2012	8-Methoxypsoralen plus UVA treatment increases the proportion of CLA+ CD25+ CD4+ T cells in lymph nodes of K5.hTGFbeta1 transgenic mice.	Methoxsalen	0-17	selectin P ligand	Homo sapiens	65-68
22379972-0	2012	8-Methoxypsoralen plus UVA treatment increases the proportion of CLA+ CD25+ CD4+ T cells in lymph nodes of K5.hTGFbeta1 transgenic mice.	Methoxsalen	0-17	interleukin 2 receptor subunit alpha	Homo sapiens	70-74
22379972-0	2012	8-Methoxypsoralen plus UVA treatment increases the proportion of CLA+ CD25+ CD4+ T cells in lymph nodes of K5.hTGFbeta1 transgenic mice.	Methoxsalen	0-17	transforming growth factor beta 1	Homo sapiens	110-119
21967523-9	2012	Exposure of mammalian cells to 8-MOP induced gene expression via the ARE, a regulatory sequence in promoters of cytoprotective genes including GSTs, suggesting that these genes may be implicated in 8-MOP metabolism.	Methoxsalen	31-36	glutathione S-transferase kappa 1	Homo sapiens	143-147
22173200-8	2012	CYP 2E1 activity and protein expression were suppressed by psoralen and isopsoralen and increased by xanthotoxin.	Methoxsalen	101-112	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	0-7
21967523-9	2012	Exposure of mammalian cells to 8-MOP induced gene expression via the ARE, a regulatory sequence in promoters of cytoprotective genes including GSTs, suggesting that these genes may be implicated in 8-MOP metabolism.	Methoxsalen	198-203	glutathione S-transferase kappa 1	Homo sapiens	143-147
21244437-4	2011	The other two human CYP inhibitors were classified as strong inhibitors of CYP2A: 8-methoxypsoralen (CYP2A6) and alpha-naphthoflavone (CYP1A1/2).	Methoxsalen	82-99	cytochrome P450 family 2 subfamily A member 19	Sus scrofa	75-80
22467383-1	2012	Extracorporeal photopheresis (ECP or photopheresis) is an advanced therapeutic apheresis procedure in which blood is separated into its various components and the isolated buffy coat is treated with 8-methoxypsoralen (a photoactivating drug), exposed to ultraviolet light and returned to the patient.	Methoxsalen	199-216	ribonuclease A family member 3	Homo sapiens	30-33
21244437-4	2011	The other two human CYP inhibitors were classified as strong inhibitors of CYP2A: 8-methoxypsoralen (CYP2A6) and alpha-naphthoflavone (CYP1A1/2).	Methoxsalen	82-99	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	101-107
21244437-7	2011	These results of this study suggest that 8-MOP is a potent, mechanism-based inhibitor of pig CYP2A activity in pig liver microsomes.	Methoxsalen	41-46	cytochrome P450 family 2 subfamily A member 19	Sus scrofa	93-98
20638260-5	2010	Compared with 8-Methoxypsoralen, an effective tyrosinase activator with an EC(50) of 7.26 muM, 3 compounds exhibited smaller EC(50) values (apigenin, 0.45 muM; hyperosid, 0.92 muM; and icariin, 1.01 muM for enhancing tyrosinase activity).	Methoxsalen	14-31	tyrosinase	Mus musculus	46-56
21778904-6	2011	Extracorporeal photochemotherapy has been shown to be effective in the treatment of CTCL consisting of reinfusion of 3 to 9 x 10 leukocytes, taken from the patient by leukopheresis and treated in an extracorporeal system with 8-methoxypsoralen and UVA.	Methoxsalen	226-243	TSPY like 2	Homo sapiens	84-88
21273683-4	2010	The time courses of protection by bergapten, imperatorin, oxypeucedanin and xanthotoxin against maximal electroshock-induced seizures revealed that 300 mg/kg imperatorin and xanthotoxin (C-8 substituted derivatives of psoralen) exerted strong anticonvulsant activity, whereas 300 mg/kg bergapten and oxypeucedanin (C-5 substituted derivatives of psoralen) did not produce any anticonvulsant activity in this model.	Methoxsalen	76-87	cell division cycle associated 3	Mus musculus	187-190
20880231-0	2010	Inhibition of histidine ammonia lyase by 8-methoxypsoralen and psoralen-oxidized photoproducts.	Methoxsalen	41-58	histidine ammonia-lyase	Homo sapiens	14-37
20880231-1	2010	The effect of 8-methoxypsoralen-UVA therapy on the catalysis of histidine to trans-urocanic acid by histidine ammonia lyase (HAL, EC 4.3.1.3) was examined using an enzymatic assay from Sigma-Aldrich where the growth of the trans-urocanic acid peak at 277 nm was monitored.	Methoxsalen	14-31	histidine ammonia-lyase	Homo sapiens	100-123
20880231-1	2010	The effect of 8-methoxypsoralen-UVA therapy on the catalysis of histidine to trans-urocanic acid by histidine ammonia lyase (HAL, EC 4.3.1.3) was examined using an enzymatic assay from Sigma-Aldrich where the growth of the trans-urocanic acid peak at 277 nm was monitored.	Methoxsalen	14-31	histidine ammonia-lyase	Homo sapiens	125-128
21273683-4	2010	The time courses of protection by bergapten, imperatorin, oxypeucedanin and xanthotoxin against maximal electroshock-induced seizures revealed that 300 mg/kg imperatorin and xanthotoxin (C-8 substituted derivatives of psoralen) exerted strong anticonvulsant activity, whereas 300 mg/kg bergapten and oxypeucedanin (C-5 substituted derivatives of psoralen) did not produce any anticonvulsant activity in this model.	Methoxsalen	174-185	cell division cycle associated 3	Mus musculus	187-190
21273683-4	2010	The time courses of protection by bergapten, imperatorin, oxypeucedanin and xanthotoxin against maximal electroshock-induced seizures revealed that 300 mg/kg imperatorin and xanthotoxin (C-8 substituted derivatives of psoralen) exerted strong anticonvulsant activity, whereas 300 mg/kg bergapten and oxypeucedanin (C-5 substituted derivatives of psoralen) did not produce any anticonvulsant activity in this model.	Methoxsalen	174-185	hemolytic complement	Mus musculus	315-318
21475870-0	2009	8-Methoxypsoralen, a potent human CYP2A6 inhibitor, inhibits lung adenocarcinoma development induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A/J mice.	Methoxsalen	0-17	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	34-40
20488788-0	2010	8-methoxypsoralen plus ultraviolet A therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3+ regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder.	Methoxsalen	0-17	interleukin 23, alpha subunit p19	Mus musculus	72-77
20488788-0	2010	8-methoxypsoralen plus ultraviolet A therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3+ regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder.	Methoxsalen	0-17	forkhead box P3	Mus musculus	105-110
20488788-0	2010	8-methoxypsoralen plus ultraviolet A therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3+ regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder.	Methoxsalen	0-17	cytotoxic T-lymphocyte-associated protein 4	Mus musculus	141-146
20394727-0	2010	Uptake of donor lymphocytes treated with 8-methoxypsoralen and ultraviolet A light by recipient dendritic cells induces CD4+CD25+Foxp3+ regulatory T cells and down-regulates cardiac allograft rejection.	Methoxsalen	41-58	CD4 molecule	Homo sapiens	120-123
20394727-0	2010	Uptake of donor lymphocytes treated with 8-methoxypsoralen and ultraviolet A light by recipient dendritic cells induces CD4+CD25+Foxp3+ regulatory T cells and down-regulates cardiac allograft rejection.	Methoxsalen	41-58	interferon stimulated exonuclease gene 20	Homo sapiens	124-128
20394727-0	2010	Uptake of donor lymphocytes treated with 8-methoxypsoralen and ultraviolet A light by recipient dendritic cells induces CD4+CD25+Foxp3+ regulatory T cells and down-regulates cardiac allograft rejection.	Methoxsalen	41-58	forkhead box P3	Homo sapiens	129-134
19702528-10	2009	Selegiline, methoxsalen, (R)-(+) menthofuran and decursinol angelate are mechanism-based inhibitors of CYP2A6.	Methoxsalen	12-23	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	103-109
20415644-6	2010	Another member of the psoralen family, 8-methoxypsoralen, was also found to rescue gata1 expression in cdx4-mutant embryos.	Methoxsalen	39-56	GATA binding protein 1a	Danio rerio	83-88
20415644-6	2010	Another member of the psoralen family, 8-methoxypsoralen, was also found to rescue gata1 expression in cdx4-mutant embryos.	Methoxsalen	39-56	caudal type homeobox 4	Danio rerio	103-107
21475870-11	2009	These results clearly demonstrate that methoxsalen, a potent human CYP2A6 inhibitor, inhibits not only lung adenoma but also adenocarcinoma development.	Methoxsalen	39-50	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	67-73
21475870-1	2009	Previously, we demonstrated that 8-methoxypsoralen (methoxsalen), a potent human cytochrome P450 2A6 (CYP2A6) inhibitor, strongly suppresses lung adenoma induction by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in female A/J mice.	Methoxsalen	33-50	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	81-100
21475870-1	2009	Previously, we demonstrated that 8-methoxypsoralen (methoxsalen), a potent human cytochrome P450 2A6 (CYP2A6) inhibitor, strongly suppresses lung adenoma induction by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in female A/J mice.	Methoxsalen	33-50	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	102-108
21475870-1	2009	Previously, we demonstrated that 8-methoxypsoralen (methoxsalen), a potent human cytochrome P450 2A6 (CYP2A6) inhibitor, strongly suppresses lung adenoma induction by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in female A/J mice.	Methoxsalen	52-63	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	81-100
21475870-1	2009	Previously, we demonstrated that 8-methoxypsoralen (methoxsalen), a potent human cytochrome P450 2A6 (CYP2A6) inhibitor, strongly suppresses lung adenoma induction by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in female A/J mice.	Methoxsalen	52-63	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	102-108
17671098-8	2007	Furthermore, the addition of 8-methoxypsoralen, a CYP2A inhibitor, led to greater inhibition of NNK metabolic activation in microsomes containing relatively high levels of CYP2A13 than in samples containing no detectable CYP2A13.	Methoxsalen	29-46	cytochrome P450 family 2 subfamily A member 13	Homo sapiens	50-55
18990727-11	2009	In CYP2E1-null mice, aminobenzotriazole and methoxsalen, but not diallylsulfide, blocked allylnitrile-induced vestibular toxicity.	Methoxsalen	44-55	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	3-9
18813816-1	2008	Pretreatment with 8-methoxypsoralen (8-MOP), a potent human CYP2A6 inhibitor, strongly suppresses lung tumorigenesis by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in female A/J mice.	Methoxsalen	18-35	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	60-66
18813816-1	2008	Pretreatment with 8-methoxypsoralen (8-MOP), a potent human CYP2A6 inhibitor, strongly suppresses lung tumorigenesis by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in female A/J mice.	Methoxsalen	37-42	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	60-66
18291319-3	2008	The therapeutic compound 8-methoxypsoralen was hydroxylated by plants overexpressing CYP82C2 or CYP82C4, forming 5-hydroxy-8-methoxypsoralen.	Methoxsalen	25-42	cytochrome P450, family 82, subfamily C, polypeptide 2	Arabidopsis thaliana	85-92
18291319-3	2008	The therapeutic compound 8-methoxypsoralen was hydroxylated by plants overexpressing CYP82C2 or CYP82C4, forming 5-hydroxy-8-methoxypsoralen.	Methoxsalen	25-42	cytochrome P450, family 82, subfamily C, polypeptide 4	Arabidopsis thaliana	96-103
19318276-0	2009	Slt2 (Mpk1) MAP kinase is involved in the response of Saccharomyces cerevisiae to 8-methoxypsoralen plus UVA.	Methoxsalen	82-99	mitogen-activated serine/threonine-protein kinase SLT2	Saccharomyces cerevisiae S288C	0-4
19318276-0	2009	Slt2 (Mpk1) MAP kinase is involved in the response of Saccharomyces cerevisiae to 8-methoxypsoralen plus UVA.	Methoxsalen	82-99	mitogen-activated serine/threonine-protein kinase SLT2	Saccharomyces cerevisiae S288C	6-10
18215451-0	2008	Different modes of inhibition of mouse Cyp2a5 and rat CYP2A3 by the food-derived 8-methoxypsoralen.	Methoxsalen	81-98	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	39-45
18215451-0	2008	Different modes of inhibition of mouse Cyp2a5 and rat CYP2A3 by the food-derived 8-methoxypsoralen.	Methoxsalen	81-98	cytochrome P450, family 2, subfamily a, polypeptide 3	Rattus norvegicus	54-60
18215451-3	2008	8-Methoxypsoralen (8-MOP) is a mechanism-based inhibitor of human CYP2A6 and CYP2A13.	Methoxsalen	0-17	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	66-72
18215451-3	2008	8-Methoxypsoralen (8-MOP) is a mechanism-based inhibitor of human CYP2A6 and CYP2A13.	Methoxsalen	0-17	cytochrome P450 family 2 subfamily A member 13	Homo sapiens	77-84
18215451-3	2008	8-Methoxypsoralen (8-MOP) is a mechanism-based inhibitor of human CYP2A6 and CYP2A13.	Methoxsalen	19-24	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	66-72
18215451-3	2008	8-Methoxypsoralen (8-MOP) is a mechanism-based inhibitor of human CYP2A6 and CYP2A13.	Methoxsalen	19-24	cytochrome P450 family 2 subfamily A member 13	Homo sapiens	77-84
18215451-4	2008	8-MOP is also an inhibitor of Cyp2a5, but the mode of this inhibition is unknown.	Methoxsalen	0-5	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	30-36
18215451-5	2008	There is no published data on the inhibition of CYP2A3 by 8-MOP.	Methoxsalen	58-63	cytochrome P450, family 2, subfamily a, polypeptide 3	Rattus norvegicus	48-54
18215451-8	2008	By contrast, 8-MOP was able to inhibit CYP2A3-mediated coumarin 7-hydroxylase only in a non-competitive way (K(iu)=0.22 microM).	Methoxsalen	13-18	cytochrome P450, family 2, subfamily a, polypeptide 3	Rattus norvegicus	39-45
18215451-8	2008	By contrast, 8-MOP was able to inhibit CYP2A3-mediated coumarin 7-hydroxylase only in a non-competitive way (K(iu)=0.22 microM).	Methoxsalen	13-18	cytochrome P450, family 2, subfamily a, polypeptide 3	Rattus norvegicus	55-77
18215451-9	2008	In conclusion, we showed that 8-MOP inhibits Cyp2a5 and CYP2A3 through different mechanisms.	Methoxsalen	30-35	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	45-51
18215451-9	2008	In conclusion, we showed that 8-MOP inhibits Cyp2a5 and CYP2A3 through different mechanisms.	Methoxsalen	30-35	cytochrome P450, family 2, subfamily a, polypeptide 3	Rattus norvegicus	56-62
18098062-7	2008	Methoxsalen, an irreversible inhibitor of CYP2A5, significantly reduced the metabolic elimination of nicotine in vivo, but the reversible inhibitors had no effect.	Methoxsalen	0-11	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	42-48
17671098-8	2007	Furthermore, the addition of 8-methoxypsoralen, a CYP2A inhibitor, led to greater inhibition of NNK metabolic activation in microsomes containing relatively high levels of CYP2A13 than in samples containing no detectable CYP2A13.	Methoxsalen	29-46	cytochrome P450 family 2 subfamily A member 13	Homo sapiens	172-179
17671098-8	2007	Furthermore, the addition of 8-methoxypsoralen, a CYP2A inhibitor, led to greater inhibition of NNK metabolic activation in microsomes containing relatively high levels of CYP2A13 than in samples containing no detectable CYP2A13.	Methoxsalen	29-46	cytochrome P450 family 2 subfamily A member 13	Homo sapiens	221-228
17021260-1	2007	Studies were undertaken to examine whether methoxsalen (9-methoxyfuro[3,2-g][1]benzopyran-7-one), a specific and relatively selective inhibitor of human CYP2A6, inhibited CYP2A5-mediated nicotine metabolism in vitro.	Methoxsalen	43-54	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	153-159
17021260-1	2007	Studies were undertaken to examine whether methoxsalen (9-methoxyfuro[3,2-g][1]benzopyran-7-one), a specific and relatively selective inhibitor of human CYP2A6, inhibited CYP2A5-mediated nicotine metabolism in vitro.	Methoxsalen	56-95	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	153-159
15271205-2	2004	As the xenobiotic response element to xanthotoxin (XRE-xan) is necessary but not sufficient for transcription of the CYP6B1v3 gene in Sf9 cells, sequences upstream of it, such as a putative EcRE, and downstream of it, such as a putative C/EBP binding site and Inr, have been tested for their roles in regulation.	Methoxsalen	38-49	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	237-242
17003103-0	2007	Photochemotherapeutic agent 8-methoxypsoralen induces cytochrome P450 3A4 and carboxylesterase HCE2: evidence on an involvement of the pregnane X receptor.	Methoxsalen	28-45	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	54-73
17003103-0	2007	Photochemotherapeutic agent 8-methoxypsoralen induces cytochrome P450 3A4 and carboxylesterase HCE2: evidence on an involvement of the pregnane X receptor.	Methoxsalen	28-45	carboxylesterase 2	Homo sapiens	95-99
17003103-0	2007	Photochemotherapeutic agent 8-methoxypsoralen induces cytochrome P450 3A4 and carboxylesterase HCE2: evidence on an involvement of the pregnane X receptor.	Methoxsalen	28-45	nuclear receptor subfamily 1 group I member 2	Homo sapiens	135-154
17003103-3	2007	In this study, we report that 8-MOP is a potent inducer of cytochrome P450 3A4 (CYP3A4) and carboxylesterase 2 (HCE2), two major human enzymes that catalyze oxidative and hydrolytic reactions, respectively.	Methoxsalen	30-35	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	59-78
17003103-3	2007	In this study, we report that 8-MOP is a potent inducer of cytochrome P450 3A4 (CYP3A4) and carboxylesterase 2 (HCE2), two major human enzymes that catalyze oxidative and hydrolytic reactions, respectively.	Methoxsalen	30-35	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	80-86
17003103-3	2007	In this study, we report that 8-MOP is a potent inducer of cytochrome P450 3A4 (CYP3A4) and carboxylesterase 2 (HCE2), two major human enzymes that catalyze oxidative and hydrolytic reactions, respectively.	Methoxsalen	30-35	carboxylesterase 2	Homo sapiens	92-110
17003103-3	2007	In this study, we report that 8-MOP is a potent inducer of cytochrome P450 3A4 (CYP3A4) and carboxylesterase 2 (HCE2), two major human enzymes that catalyze oxidative and hydrolytic reactions, respectively.	Methoxsalen	30-35	carboxylesterase 2	Homo sapiens	112-116
17003103-4	2007	In human primary hepatocytes, 8-MOP markedly induced the expression of CYP3A4 (approximately sixfold) and HCE2 (approximately threefold) and the induction occurred in a concentration-dependent manner (0-50 microM).	Methoxsalen	30-35	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	71-77
17003103-4	2007	In human primary hepatocytes, 8-MOP markedly induced the expression of CYP3A4 (approximately sixfold) and HCE2 (approximately threefold) and the induction occurred in a concentration-dependent manner (0-50 microM).	Methoxsalen	30-35	carboxylesterase 2	Homo sapiens	106-110
17003103-6	2007	In a reporter assay, 8-MOP stimulated both CYP3A4 and HCE2 promoters, and the stimulation was enhanced by cotransfection of PXR.	Methoxsalen	21-26	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-49
17003103-6	2007	In a reporter assay, 8-MOP stimulated both CYP3A4 and HCE2 promoters, and the stimulation was enhanced by cotransfection of PXR.	Methoxsalen	21-26	carboxylesterase 2	Homo sapiens	54-58
17003103-6	2007	In a reporter assay, 8-MOP stimulated both CYP3A4 and HCE2 promoters, and the stimulation was enhanced by cotransfection of PXR.	Methoxsalen	21-26	nuclear receptor subfamily 1 group I member 2	Homo sapiens	124-127
17003103-7	2007	Several natural variants of PXR differed markedly from the wild-type receptor in responding to 8-MOP.	Methoxsalen	95-100	nuclear receptor subfamily 1 group I member 2	Homo sapiens	28-31
16762476-6	2006	The apiaceous constituents psoralen, 5-methoxypsoralen (5-MOP), 8-methoxypsoralen (8-MOP), and apigenin were potent inhibitors of hCYP1A2-mediated MROD activity in yeast microsomes, whereas quercetin was a modest hCYP1A2 inhibitor.	Methoxsalen	64-81	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	130-137
16762476-6	2006	The apiaceous constituents psoralen, 5-methoxypsoralen (5-MOP), 8-methoxypsoralen (8-MOP), and apigenin were potent inhibitors of hCYP1A2-mediated MROD activity in yeast microsomes, whereas quercetin was a modest hCYP1A2 inhibitor.	Methoxsalen	64-81	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	213-220
16762476-6	2006	The apiaceous constituents psoralen, 5-methoxypsoralen (5-MOP), 8-methoxypsoralen (8-MOP), and apigenin were potent inhibitors of hCYP1A2-mediated MROD activity in yeast microsomes, whereas quercetin was a modest hCYP1A2 inhibitor.	Methoxsalen	83-88	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	130-137
16821791-2	2006	Compounds 7 and 10 showed a strong photoantiproliferative activity, up to 3 orders of magnitude higher than that of the photochemotherapeutic drug 8-methoxypsoralen (8-MOP).	Methoxsalen	147-164	neurolysin	Homo sapiens	168-171
15958517-1	2005	Recently we reported that the occurrence of lung adenoma caused by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) was completely prevented by pretreatment of female A/J mice with 8-methoxypsoralen, a potent inhibitor of cytochrome P450 (P450 or CYP) 2A [Takeuchi et al.	Methoxsalen	185-202	cytochrome P450, family 2, subfamily a	Mus musculus	243-258
15958517-3	2005	Thus, the aim of this study was to confirm that 8-methoxypsoralen exhibits chemopreventive effects by inhibiting CYP2A in the mouse lung.	Methoxsalen	48-65	cytochrome P450, family 2, subfamily a	Mus musculus	113-118
15958517-4	2005	The involvement of CYP2A in the metabolic activation of NNK in the lung was first evidenced by the fact that the mutagenic activation of NNK by mouse lung microsomes was inhibited by 8-methoxypsoralen, coumarin and antibodies to rat CYP2A1.	Methoxsalen	183-200	cytochrome P450, family 2, subfamily a	Mus musculus	19-24
15958517-7	2005	In accordance with these in vitro data, treatment of gpt delta transgenic mice with 8-methoxypsoralen prior to NNK completely inhibited the mutation of the gpt delta gene.	Methoxsalen	84-101	glutamic pyruvic transaminase, soluble	Mus musculus	53-56
15958517-7	2005	In accordance with these in vitro data, treatment of gpt delta transgenic mice with 8-methoxypsoralen prior to NNK completely inhibited the mutation of the gpt delta gene.	Methoxsalen	84-101	glutamic pyruvic transaminase, soluble	Mus musculus	156-159
15958517-8	2005	The in vivo chemopreventive effects of 8-methoxypsoralen towards NNK-induced adenoma was seen only when the agent was given to female A/J mice prior to, but not posterior to, NNK, lending support to the idea that NNK is activated by CYP2A5 in the mouse lung as an initial step to cause adenoma.	Methoxsalen	39-56	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	233-239
15958517-10	2005	To our surprise, CYP2A protein(s) was expressed in the lesion of NNK-induced lung adenomas, probably suggesting that 8-methoxypsoralen could inhibit the possible occurrence of further mutation of the adenoma cells induced by NNK.	Methoxsalen	117-134	cytochrome P450, family 2, subfamily a	Mus musculus	17-22
15958517-11	2005	Based on these lines of evidence, we propose that 8-methoxypsoralen inhibits the CYP2A5-mediated metabolic activation of NNK in the mouse lung, leading to the prevention of NNK-induced adenoma.	Methoxsalen	50-67	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	81-87
16086027-0	2005	Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen.	Methoxsalen	79-90	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	31-50
15670584-3	2005	We have investigated the interaction of four furocoumarins angelicin, bergamottin, isopimpinellin, and 8-methoxypsoralen with the expression and activity of aryl hydrocarbon receptor (AhR)-regulated CYP1A1 in rat hepatocytes in primary culture, both in the presence and absence of light.	Methoxsalen	103-120	aryl hydrocarbon receptor	Rattus norvegicus	157-182
15670584-3	2005	We have investigated the interaction of four furocoumarins angelicin, bergamottin, isopimpinellin, and 8-methoxypsoralen with the expression and activity of aryl hydrocarbon receptor (AhR)-regulated CYP1A1 in rat hepatocytes in primary culture, both in the presence and absence of light.	Methoxsalen	103-120	aryl hydrocarbon receptor	Rattus norvegicus	184-187
15670584-3	2005	We have investigated the interaction of four furocoumarins angelicin, bergamottin, isopimpinellin, and 8-methoxypsoralen with the expression and activity of aryl hydrocarbon receptor (AhR)-regulated CYP1A1 in rat hepatocytes in primary culture, both in the presence and absence of light.	Methoxsalen	103-120	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	199-205
15670584-5	2005	8-Methoxypsoralen and angelicin led to a significant induction of CYP1A1 mRNA in hepatocytes, while all furocoumarins except bergamottin increased xenobiotic-responsive element-driven reporter gene expression in transfected H4IIE rat hepatoma cells when light was excluded.	Methoxsalen	0-17	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	66-72
15711930-0	2005	Antiapoptotic role of p38 mitogen activated protein kinase in Jurkat T cells and normal human T lymphocytes treated with 8-methoxypsoralen and ultraviolet-A radiation.	Methoxsalen	121-138	mitogen-activated protein kinase 14	Homo sapiens	22-25
16501006-5	2006	Furthermore, inhibition of CYP2A, as assayed by coumarin 7-hydroxylase activity, using 8-methoxypsoralen and diethyldithiocarbamate was not associated with any further significant inhibition of the production of 3MI metabolites.	Methoxsalen	87-104	cytochrome P450 family 2 subfamily A member 19	Sus scrofa	27-32
16501006-5	2006	Furthermore, inhibition of CYP2A, as assayed by coumarin 7-hydroxylase activity, using 8-methoxypsoralen and diethyldithiocarbamate was not associated with any further significant inhibition of the production of 3MI metabolites.	Methoxsalen	87-104	cytochrome P450 family 2 subfamily A member 19	Sus scrofa	48-70
15893417-1	2006	We have reported that pretreatment by stomach tube with 8-methoxypsoralen (methoxsalen; 8-MOP), a potent human CYP2A6 inhibitor, strongly suppresses lung tumorigenesis by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in female A/J mice (Cancer Res.	Methoxsalen	56-73	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	111-117
15893417-1	2006	We have reported that pretreatment by stomach tube with 8-methoxypsoralen (methoxsalen; 8-MOP), a potent human CYP2A6 inhibitor, strongly suppresses lung tumorigenesis by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in female A/J mice (Cancer Res.	Methoxsalen	75-86	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	111-117
15893417-1	2006	We have reported that pretreatment by stomach tube with 8-methoxypsoralen (methoxsalen; 8-MOP), a potent human CYP2A6 inhibitor, strongly suppresses lung tumorigenesis by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in female A/J mice (Cancer Res.	Methoxsalen	88-93	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	111-117
15893417-11	2006	In conclusion, the results of this study showed that clear dose response inhibitory effects of 8-MOP on NNK-induced lung tumorigenesis in female A/J mice fed diets containing 8-MOP, due to inhibition of enzyme activity of CYP2A4 and CYP2A5, rather than their gene expression.	Methoxsalen	95-100	cytochrome P450, family 2, subfamily a, polypeptide 4	Mus musculus	222-228
15893417-11	2006	In conclusion, the results of this study showed that clear dose response inhibitory effects of 8-MOP on NNK-induced lung tumorigenesis in female A/J mice fed diets containing 8-MOP, due to inhibition of enzyme activity of CYP2A4 and CYP2A5, rather than their gene expression.	Methoxsalen	95-100	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	233-239
15893417-11	2006	In conclusion, the results of this study showed that clear dose response inhibitory effects of 8-MOP on NNK-induced lung tumorigenesis in female A/J mice fed diets containing 8-MOP, due to inhibition of enzyme activity of CYP2A4 and CYP2A5, rather than their gene expression.	Methoxsalen	175-180	cytochrome P450, family 2, subfamily a, polypeptide 4	Mus musculus	222-228
15893417-11	2006	In conclusion, the results of this study showed that clear dose response inhibitory effects of 8-MOP on NNK-induced lung tumorigenesis in female A/J mice fed diets containing 8-MOP, due to inhibition of enzyme activity of CYP2A4 and CYP2A5, rather than their gene expression.	Methoxsalen	175-180	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	233-239
16176798-6	2005	8-Methoxypsoralen, an inhibitor of CYP2A6, efficiently prevented the occurrence of adenoma caused by NNK in A/J mice.	Methoxsalen	0-17	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	35-41
16099607-0	2005	Regulation of an insect cytochrome P450 monooxygenase gene (CYP6B1) by aryl hydrocarbon and xanthotoxin response cascades.	Methoxsalen	92-103	cytochrome P450 family 20 subfamily A member 1	Homo sapiens	24-53
16099607-3	2005	One such element is the xenobiotic response element to xanthotoxin (XRE-Xan) that lies upstream of consensus XRE-AhR (xenobiotic response element to the aryl hydrocarbon receptor) and OCT-1 (octamer-1 binding site) element known to be utilized in mammalian aryl hydrocarbon response cascades.	Methoxsalen	55-66	aryl hydrocarbon receptor	Homo sapiens	113-116
16099607-3	2005	One such element is the xenobiotic response element to xanthotoxin (XRE-Xan) that lies upstream of consensus XRE-AhR (xenobiotic response element to the aryl hydrocarbon receptor) and OCT-1 (octamer-1 binding site) element known to be utilized in mammalian aryl hydrocarbon response cascades.	Methoxsalen	55-66	aryl hydrocarbon receptor	Homo sapiens	153-178
16099607-4	2005	Two-plasmid transfections conducted in Sf9 cells have indicated that XRE-Xan, XRE-AhR and a number of other proximal elements, but not OCT-1, are critical for basal as well as xanthotoxin- and benzo[alpha]pyrene-induced transcription of the CYP6B1 promoter.	Methoxsalen	176-187	aryl hydrocarbon receptor	Homo sapiens	82-85
15902973-0	2005	Analysis of p53 tumor suppressor gene, H-ras protooncogene and proliferating cell nuclear antigen (PCNA) in squamous cell carcinomas of HRA/Skh mice following exposure to 8-methoxypsoralen (8-MOP) and UVA radiation (PUVA therapy).	Methoxsalen	171-188	transformation related protein 53, pseudogene	Mus musculus	12-15
15271205-4	2004	Mutation of the more proximal promoter sequence, including the C/EBP and Inr, have indicated that many core promoter elements between the TATA box and translation start site modulate basal and xanthotoxin-inducible expression of this composite promoter.	Methoxsalen	193-204	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	63-68
15075081-0	2004	Caspase-9 is the upstream caspase activated by 8-methoxypsoralen and ultraviolet-A radiation treatment of Jurkat T leukemia cells and normal T lymphocytes.	Methoxsalen	47-64	caspase 9	Homo sapiens	0-9
12473064-3	2002	Lipopolysaccharide stimulated IL-8 production in 8-MOP-phototreated PBMC more efficiently than those untreated or treated with 8-MOP or UVA.	Methoxsalen	49-54	C-X-C motif chemokine ligand 8	Homo sapiens	30-34
15618749-5	2003	The formation of 5-FU from FT in human liver S9 was inhibited over 82% by 8-methoxypsoralen, a CYP2A6-selective inhibitor.	Methoxsalen	74-91	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	95-101
15052360-0	2004	UVA activated 8-MOP and chlorpromazine inhibit release of TNF-alpha by post-transcriptional regulation.	Methoxsalen	14-19	tumor necrosis factor	Homo sapiens	58-67
15052360-4	2004	Based on these observations, in this study we further investigate the mechanisms of TNF-alpha inhibition by 8-MOP and CPZ photosensitization.	Methoxsalen	108-113	tumor necrosis factor	Homo sapiens	84-93
14633670-0	2003	Pretreatment with 8-methoxypsoralen, a potent human CYP2A6 inhibitor, strongly inhibits lung tumorigenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A/J mice.	Methoxsalen	18-35	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	52-58
14633670-2	2003	Methoxsalen (8-methoxypsoralen) was reported to inhibit CYP2A6.	Methoxsalen	0-11	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	56-62
14633670-2	2003	Methoxsalen (8-methoxypsoralen) was reported to inhibit CYP2A6.	Methoxsalen	13-30	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	56-62
14633670-9	2003	These results clearly demonstrated that methoxsalen, a potent human CYP2A6 inhibitor, is a strong chemopreventive agent against NNK-induction of lung tumorigenesis.	Methoxsalen	40-51	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	68-74
12679052-4	2003	Coumarin 7-hydroxylase was inhibited by 8-methoxypsoralen.	Methoxsalen	40-57	cytochrome P450, family 2, subfamily a, polypeptide 3	Rattus norvegicus	0-22
12485437-0	2002	Stimulation of melanoblast pigmentation by 8-methoxypsoralen:the involvement of microphthalmia-associated transcription factor, the protein kinase a signal pathway, and proteasome-mediated degradation.	Methoxsalen	43-60	melanocyte inducing transcription factor	Homo sapiens	80-126
12029503-0	2002	Differential effect of 8-methoxypsoralen, 4,6,4"-trimethylangelicin, and chlorpromazine on cell death and TNF-alpha production.	Methoxsalen	23-40	tumor necrosis factor	Homo sapiens	106-115
12355562-7	2002	The activity of CYP 2C6 in 5- and 8-methoxypsoralen-treated rats increased over control values after the inhibitor was withdrawn.	Methoxsalen	34-51	cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1	Rattus norvegicus	16-23
12392107-5	2002	Glibenclamide, a blocker of the cystic fibrosis transmembrane conductance regulator (CFTR), reduced the MTX-stimulated increase of Isc by 59 +/- 6%.	Methoxsalen	104-107	cystic fibrosis transmembrane conductance regulator	Mus musculus	32-83
12392107-5	2002	Glibenclamide, a blocker of the cystic fibrosis transmembrane conductance regulator (CFTR), reduced the MTX-stimulated increase of Isc by 59 +/- 6%.	Methoxsalen	104-107	cystic fibrosis transmembrane conductance regulator	Mus musculus	85-89
12392107-9	2002	These data suggest that the CFTR and IK(Ca) channels participate in the MTX-activated, sustained Cl- secretory response of the mouse jejunum.	Methoxsalen	72-75	cystic fibrosis transmembrane conductance regulator	Mus musculus	28-32
12126205-1	2002	Photopheresis, a leukapheresis-based therapy that combines 8-methoxypsoralen (8-MOP) and ultraviolet-A irradiation, has been shown to be an effective treatment for advanced cutaneous T cell lymphoma (CTCL), but also appears to be effective in certain patients with systemic sclerosis (SSc) and chronic graft versus host disease (cGVHD).	Methoxsalen	59-76	TSPY like 2	Homo sapiens	200-204
12126206-1	2002	Photopheresis (ECP) is a new immunomodulatory therapy in which recipient lymphocytes are treated extracorporeally with 8-methoxypsoralen (8-MOP) and ultraviolet light.	Methoxsalen	119-136	ribonuclease A family member 3	Homo sapiens	15-18
12126206-1	2002	Photopheresis (ECP) is a new immunomodulatory therapy in which recipient lymphocytes are treated extracorporeally with 8-methoxypsoralen (8-MOP) and ultraviolet light.	Methoxsalen	138-143	ribonuclease A family member 3	Homo sapiens	15-18
11965365-3	2002	Interestingly, for 6, a photocytotoxic ability higher in HL-60, comparable in HeLa cells, with respect to that of the well-known drug 8-methoxypsoralen (8-MOP), was demonstrated.	Methoxsalen	134-151	opioid receptor mu 1	Homo sapiens	155-158
11978740-3	2002	We found that WRN deficient primary fibroblasts, as well as lymphoblastoid cell lines (LCLs), show reduced proliferative survival in response to 4-nitroquinoline-N-oxide (4NQO) and 8-methoxypsoralen (8MOP), compared with WRN-proficient cells.	Methoxsalen	181-198	WRN RecQ like helicase	Homo sapiens	14-17
11506127-11	2001	MDA production was inhibited by the CYP2A6 inhibitor methoxsalen but not by the CYP3A4 inhibitor troleandomycin.	Methoxsalen	53-64	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	36-42
11966883-2	2002	Sequence alignments and structure comparisons of CYP6B1v1 with the mouse CYP2A5 and bacterial CYP102 proteins, which are also capable of metabolizing the linear furanocoumarin xanthotoxin (8-methoxypsoralen), suggested that Phe116, His117, Val368 and Phe484 might be active site residues.	Methoxsalen	176-187	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	73-79
11966883-2	2002	Sequence alignments and structure comparisons of CYP6B1v1 with the mouse CYP2A5 and bacterial CYP102 proteins, which are also capable of metabolizing the linear furanocoumarin xanthotoxin (8-methoxypsoralen), suggested that Phe116, His117, Val368 and Phe484 might be active site residues.	Methoxsalen	189-206	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	73-79
11861915-1	2002	We have determined the kinetics of up-regulation of the homologous recombination gene RAD51, one of the genes induced following DNA damage in isogenic haploid DNA repair-deficient mutants of Saccharomyces cerevisiae, using treatment with the DNA crosslinking agent 8-methoxypsoralen.	Methoxsalen	265-282	recombinase RAD51	Saccharomyces cerevisiae S288C	86-91
11506127-13	2001	CYP2A6-catalyzed MDA production was inhibited by methoxsalen or anti-CYP2A6 antibody.	Methoxsalen	49-60	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	0-6
11345694-1	2001	The influence of two plant coumarins, osthol and xanthotoxin, on intracellular Ca2+ ([Ca2+]i) transients evoked by TRH were studied in clonal rat pituitary GH4C1 cells.	Methoxsalen	49-60	thyrotropin releasing hormone	Rattus norvegicus	115-118
11353760-0	2001	Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro.	Methoxsalen	14-25	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	85-91
11353760-2	2001	In this study, the selective probe reactions for each major cytochrome P450 (P450) were used to evaluate the specificity and selectivity of the CYP2A6 inhibitors methoxsalen, tranylcypromine, and tryptamine in cDNA-expressing and human liver microsomes.	Methoxsalen	162-173	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	144-150
11353760-6	2001	Methoxsalen inhibited CYP2A6 (K(i) = 0.8 microM) with about 3.5- 94-fold greater potency than other P450s, except for CYP1A2 (K(i) = 0.2 microM).	Methoxsalen	0-11	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	22-28
11353760-10	2001	Tranylcypromine [particularly R-(+) isomer], tryptamine, and methoxsalen are specific and relatively selective for CYP2A6 and may be useful in vivo to decrease smoking by inhibiting nicotine metabolism with a low risk of metabolic drug interactions.	Methoxsalen	61-72	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	115-121
10719037-0	2000	p53 mutations experimentally induced by 8-methoxypsoralen plus UVA (PUVA) differ from those found in human skin cancers in PUVA-treated patients.	Methoxsalen	40-57	tumor protein p53	Homo sapiens	0-3
10946567-3	2000	Easily oxidized substrates such as tyrosine, tryptophan and guanosine monophosphate react with the 8-methoxypsoralen and several methoxy-substituted coumarin radical cations with rate constants in excess of 2 x 10(9) M-1 s-1.	Methoxsalen	99-116	tumor associated calcium signal transducer 2	Homo sapiens	217-224
11231322-0	2001	Treatment of peripheral blood mononuclear cells with 8-methoxypsoralen plus ultraviolet A radiation induces a shift in cytokine expression from a Th1 to a Th2 response.	Methoxsalen	53-70	negative elongation factor complex member C/D	Homo sapiens	146-149
11231322-4	2001	Fluorescence-activated cell sorter analysis revealed a significant reduction of interleukin-2- and interferon-gamma-producing CD4+ cells upon psoralen plus ultraviolet A treatment depending on the concentration of 8-methoxypsoralen.	Methoxsalen	214-231	interleukin 22	Homo sapiens	80-115
11231322-6	2001	These results indicate that 8-methoxypsoralen photochemotherapy of lymphocytes is able to modulate their Th1/Th2 distribution.	Methoxsalen	28-45	negative elongation factor complex member C/D	Homo sapiens	105-108
10987212-8	2000	Cocaine N-demethylation was inhibited particularly by addition of the CYP2A specific inhibitor, 8-methoxypsoralen.	Methoxsalen	96-113	cytochrome P450, family 2, subfamily a	Mus musculus	70-75
10799921-7	2000	Furthermore, addition of exogenous IL-10, but not IL-12, significantly increased the resistance of control inoculum-treated PBMCs to photoactivated 8-methoxypsoralen- and hypericin-induced apoptosis.	Methoxsalen	148-165	interleukin 10	Homo sapiens	35-40
10611136-0	2000	Single-dose methoxsalen effects on human cytochrome P-450 2A6 activity.	Methoxsalen	12-23	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	41-61
10651689-4	2000	In CTCL there is an accumulating body of evidence to show that 8-methoxypsoralen-treated cells display increased quantities of antigenic peptides at their cell surfaces, and this in turn leads to an enhanced cytotoxic response against the neoplastic T-cell population.	Methoxsalen	63-80	TSPY like 2	Homo sapiens	3-7
10911933-11	2000	Inhibiting CYP2A6 (e.g. tranylcypromine, methoxsalen) decreases smoking and the activation of procarcinogens.	Methoxsalen	41-52	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	11-17
10611136-1	2000	Methoxsalen (8-methoxypsoralen) is an effective and selective mechanism-based inhibitor of human hepatic cytochrome P-450 (CYP)2A6 in vitro, and may have utility as a clinical probe for CYP2A6-catalyzed xenobiotic metabolism in humans in vivo.	Methoxsalen	0-11	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	105-130
10611136-1	2000	Methoxsalen (8-methoxypsoralen) is an effective and selective mechanism-based inhibitor of human hepatic cytochrome P-450 (CYP)2A6 in vitro, and may have utility as a clinical probe for CYP2A6-catalyzed xenobiotic metabolism in humans in vivo.	Methoxsalen	13-30	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	105-130
10611136-2	2000	This investigation explored single-dose oral methoxsalen effects on human CYP2A6 activity in vivo, assessed by coumarin 7-hydroxylation.	Methoxsalen	45-56	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	74-80
10611136-10	2000	These results show that single-dose oral methoxsalen, in conventional doses, was a moderately effective inhibitor of human CYP2A6 activity in vivo, however, the duration of inhibition was limited.	Methoxsalen	41-52	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	123-129
10611136-11	2000	Interindividual variability in the extent of CYP2A6 inhibition appeared attributable to variability in the absorption and first-pass clearance of methoxsalen.	Methoxsalen	146-157	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	45-51
10611136-12	2000	Alternative doses, timing, and/or routes of methoxsalen administration are required for greater, longer, and more reproducible CYP2A6 inhibition than that provided by single-dose methoxsalen.	Methoxsalen	44-55	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	127-133
10362270-5	1999	Pretreatment with hepatic cytochrome P-450 monooxygenase inhibitors--cobalt chloride, isosafrole, methoxsalen, metyrapone and piperonyl butoxide-prevented or tended to suppress the hepatotoxicity induced by MMI in combination with BSO.	Methoxsalen	98-109	cytochrome P450, family 20, subfamily a, polypeptide 1	Mus musculus	26-56
10583023-11	1999	The inhibition of artemisinin metabolism in human liver microsomes by 8-methoxypsoralen (a CYP2A6 inhibitor) was 82% but CYP2A6 activity was not included in the regression tree.	Methoxsalen	70-87	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	91-97
10469304-0	1999	Treatment of T lymphocytes with 8-methoxypsoralen plus ultraviolet A induces transient but biologically active Th1-skewing cytokine production.	Methoxsalen	32-49	negative elongation factor complex member C/D	Homo sapiens	111-114
10469304-1	1999	8-Methoxypsoralen plus ultraviolet A light is suggested to shift T lymphocytes from Th2 to Th1 cells.	Methoxsalen	0-17	negative elongation factor complex member C/D	Homo sapiens	91-94
10469304-6	1999	Accordingly, the amount of interferon-gamma was elevated in culture supernatants from 8-methoxypsoralen-phototreated peripheral blood mononuclear cells, whereas interleukin-4 was significantly reduced.	Methoxsalen	86-103	interferon gamma	Homo sapiens	27-43
10469304-6	1999	Accordingly, the amount of interferon-gamma was elevated in culture supernatants from 8-methoxypsoralen-phototreated peripheral blood mononuclear cells, whereas interleukin-4 was significantly reduced.	Methoxsalen	86-103	interleukin 4	Homo sapiens	161-174
10469304-7	1999	This enhanced production of interferon-gamma, however, was found only until 3 d after 8-methoxypsoralen phototreatment and was declined by 5 d after treatment.	Methoxsalen	86-103	interferon gamma	Homo sapiens	28-44
10469304-9	1999	Our results show that 8-methoxypsoralen/ultraviolet A has a transient but biologically active Th1-skewing action in human T cells, suggesting that 8-methoxypsoralen/ultraviolet A exerts a beneficial therapeutic effect on Th2-mediated or Th2-malignant diseases.	Methoxsalen	22-39	negative elongation factor complex member C/D	Homo sapiens	94-97
10469304-9	1999	Our results show that 8-methoxypsoralen/ultraviolet A has a transient but biologically active Th1-skewing action in human T cells, suggesting that 8-methoxypsoralen/ultraviolet A exerts a beneficial therapeutic effect on Th2-mediated or Th2-malignant diseases.	Methoxsalen	147-164	negative elongation factor complex member C/D	Homo sapiens	94-97
9394031-0	1997	Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen.	Methoxsalen	67-84	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	44-63
9774143-5	1998	This inhibiting effect was not dependent on the CYP1A1 activity, as it also occurred in the presence of CYP1A1 inhibitors such as alpha-naphthoflavone, 8-methoxypsoralen or ellipticin.	Methoxsalen	152-169	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	104-110
9683673-1	1998	Mitotic recombination within the ARG4 gene of Saccharomyces cerevisiae was analysed after treatment of cells with the recombinogenic agent 8-methoxypsoralen (8-MOP) plus UVA.	Methoxsalen	139-156	argininosuccinate lyase ARG4	Saccharomyces cerevisiae S288C	33-37
9683673-1	1998	Mitotic recombination within the ARG4 gene of Saccharomyces cerevisiae was analysed after treatment of cells with the recombinogenic agent 8-methoxypsoralen (8-MOP) plus UVA.	Methoxsalen	158-163	argininosuccinate lyase ARG4	Saccharomyces cerevisiae S288C	33-37
9472004-3	1998	Here we show that treatment of fibroblasts with 8-methoxypsoralen (8-MOP) and subsequent ultraviolet A (UVA) irradiation resulted in a permanent switch of mitotic to stably postmitotic fibroblasts which acquired a high level of de novo expression of SA-beta-galactosidase, a marker for fibroblast senescence in vitro and in vivo.	Methoxsalen	48-65	galactosidase beta 1	Homo sapiens	253-271
9890552-5	1999	Moreover, alpha-naphthoflavone, a partial aryl hydrocarbon receptor (AhR) antagonist, and 8-methoxypsoralen, which interferes with the binding of activated AhR to the xenobiotic responsive element, were shown to suppress CYP1A1 induction when added to the cultures.	Methoxsalen	90-107	aryl hydrocarbon receptor	Homo sapiens	69-72
9890552-5	1999	Moreover, alpha-naphthoflavone, a partial aryl hydrocarbon receptor (AhR) antagonist, and 8-methoxypsoralen, which interferes with the binding of activated AhR to the xenobiotic responsive element, were shown to suppress CYP1A1 induction when added to the cultures.	Methoxsalen	90-107	aryl hydrocarbon receptor	Homo sapiens	156-159
9890552-5	1999	Moreover, alpha-naphthoflavone, a partial aryl hydrocarbon receptor (AhR) antagonist, and 8-methoxypsoralen, which interferes with the binding of activated AhR to the xenobiotic responsive element, were shown to suppress CYP1A1 induction when added to the cultures.	Methoxsalen	90-107	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	221-227
9512924-4	1997	Coumarin 7-hydroxylation in human and African green monkey was selectively inhibited by methoxsalen and pilocarpine (CYP2A6 inhibitors) but not by other inhibitors, i.e. alpha-naphthoflavone (CYP1A1), orphenadrine (CYP2B6), sulfaphenazole (CYP2C9), quinidine (CYP2D6) and ketoconazole (CYP3A4).	Methoxsalen	88-99	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	260-266
10072807-2	1997	METHOD: Observe effects of 8-MOP on the isolated human pulmonary artery rings(PAR) obtained from 11 patients undergoing lobectomy for lung carcinoma.	Methoxsalen	27-32	jumping translocation breakpoint	Homo sapiens	78-81
10072807-3	1997	RESULTS: (1)8-MOP(2 x 10(-5) mol/L) caused significant relaxation of PAR precontracted with noradreline (NA) by 88% (P < 0.001) and this effect of 8-MOP was independent on the endothelium of the pulmonary arteries.	Methoxsalen	12-17	jumping translocation breakpoint	Homo sapiens	69-72
9080365-10	1997	The effect of muscarinic stimulation on the cotransporter can, however, be blocked by inhibitors of phospholipase A2 (4-bromophenacylbromide and manoalide), by a general inhibitor of arachidonic acid metabolism (5,8,11,14-eicosatetraynoic acid) and by specific inhibitors of the cytochrome P450 pathway (methoxsalen and ketoconazole).	Methoxsalen	304-315	phospholipase A2 group IB	Rattus norvegicus	100-116
9143352-9	1997	One of the most potent inhibitors of coumarin 7-hydroxylase was 8-methoxypsoralen (methoxsalen), which was determined to be a mechanism-based inhibitor (suicide substrate) of CYP2A6 (k(inactivation) 0.5 min-1).	Methoxsalen	64-81	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	37-59
9143352-9	1997	One of the most potent inhibitors of coumarin 7-hydroxylase was 8-methoxypsoralen (methoxsalen), which was determined to be a mechanism-based inhibitor (suicide substrate) of CYP2A6 (k(inactivation) 0.5 min-1).	Methoxsalen	64-81	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	175-181
9143352-9	1997	One of the most potent inhibitors of coumarin 7-hydroxylase was 8-methoxypsoralen (methoxsalen), which was determined to be a mechanism-based inhibitor (suicide substrate) of CYP2A6 (k(inactivation) 0.5 min-1).	Methoxsalen	83-94	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	37-59
9143352-9	1997	One of the most potent inhibitors of coumarin 7-hydroxylase was 8-methoxypsoralen (methoxsalen), which was determined to be a mechanism-based inhibitor (suicide substrate) of CYP2A6 (k(inactivation) 0.5 min-1).	Methoxsalen	83-94	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	175-181
9169082-5	1997	When alpha-naphthoflavone, a partial Ah receptor (AhR) antagonist, and 8-methoxypsoralen, which interferes with the binding of activated AhR to the xenobiotic responsive element (XRE), were added to the cultures, CYP1A1 induction was suppressed.	Methoxsalen	71-88	aryl hydrocarbon receptor	Homo sapiens	137-140
9169082-5	1997	When alpha-naphthoflavone, a partial Ah receptor (AhR) antagonist, and 8-methoxypsoralen, which interferes with the binding of activated AhR to the xenobiotic responsive element (XRE), were added to the cultures, CYP1A1 induction was suppressed.	Methoxsalen	71-88	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	213-219
9039977-1	1997	8-methoxypsoralen (8-MOP), 5-methoxypsoralen (5-MOP) and 4,5",8-trimethylpsoralen (TMP) are commonly used in PUVA therapy [psoralen (P) + ultraviolet light A (UVA) irradiation] to treat skin diseases such as psoriasis and vitiligo.	Methoxsalen	0-17	opioid receptor mu 1	Homo sapiens	21-24
9077132-6	1997	At 0.1 microgram/mL of 8-MOP, maximal activation occurred with 18 J/cm2, 30 h after light exposure, With Pc 4 at 20 nM, over 90% of HeLa cells were killed after 24 h when exposed to 1 J/cm2 of red light.	Methoxsalen	23-28	proprotein convertase subtilisin/kexin type 4	Homo sapiens	105-109
9267752-2	1997	METHODS: Four consecutive AIDS patients with psoriasis and CD4 count lower than 20/mm3 were treated with 8-methoxypsoralen and UVA (PUVA).	Methoxsalen	105-122	CD4 molecule	Homo sapiens	59-62
8863822-9	1996	Consistent with CYP2A3 being a major catalyst in microsomal metabolism of DCBN, the activities of both CYP2A3 and rat olfactory microsomes in DCBN metabolism were inhibited strongly by metyrapone and methoxsalen (ID50 < 1 microM, with DCBN at 30 microM), but only marginally by 4-methylpyrazole, an inhibitor of CYP2E1.	Methoxsalen	200-211	cytochrome P450, family 2, subfamily a, polypeptide 3	Rattus norvegicus	16-22
8863822-9	1996	Consistent with CYP2A3 being a major catalyst in microsomal metabolism of DCBN, the activities of both CYP2A3 and rat olfactory microsomes in DCBN metabolism were inhibited strongly by metyrapone and methoxsalen (ID50 < 1 microM, with DCBN at 30 microM), but only marginally by 4-methylpyrazole, an inhibitor of CYP2E1.	Methoxsalen	200-211	cytochrome P450, family 2, subfamily a, polypeptide 3	Rattus norvegicus	103-109
8863822-9	1996	Consistent with CYP2A3 being a major catalyst in microsomal metabolism of DCBN, the activities of both CYP2A3 and rat olfactory microsomes in DCBN metabolism were inhibited strongly by metyrapone and methoxsalen (ID50 < 1 microM, with DCBN at 30 microM), but only marginally by 4-methylpyrazole, an inhibitor of CYP2E1.	Methoxsalen	200-211	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	315-321
8863822-10	1996	In contrast, the activity of CYP2A6 was only weakly inhibited by metyrapone or methoxsalen (ID50 > 50 microM).	Methoxsalen	79-90	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	29-35
8956358-0	1996	Phototesting in bath-PUVA: marked reduction of 8-methoxypsoralen (8-MOP) activity within one hour after an 8-MOP bath.	Methoxsalen	47-64	opioid receptor mu 1	Homo sapiens	68-71
8755585-0	1996	Signature p53 mutation at DNA cross-linking sites in 8-methoxypsoralen and ultraviolet A (PUVA)-induced murine skin cancers.	Methoxsalen	53-70	transformation related protein 53, pseudogene	Mus musculus	10-13
8819299-9	1996	Methoxsalen (CYP2A6 inhibitor) inhibited the metabolic activity of CYP1A2 as well as that of CYP2A6.	Methoxsalen	0-11	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	13-19
8819299-9	1996	Methoxsalen (CYP2A6 inhibitor) inhibited the metabolic activity of CYP1A2 as well as that of CYP2A6.	Methoxsalen	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	67-73
8819299-9	1996	Methoxsalen (CYP2A6 inhibitor) inhibited the metabolic activity of CYP1A2 as well as that of CYP2A6.	Methoxsalen	0-11	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	93-99
8596155-1	1995	OBJECTIVE: Having previously found that treating small areas of synovitis within the knees of patients with rheumatoid arthritis (RA) with 8-methoxypsoralen (8-MOP) and laser-derived ultraviolet A (PUVA) resulted in decreases in adhesion molecule expression, we sought to determine the effect of PUVA on expression of vascular cellular adhesion molecule 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), and E-selection by human umbilical vein endothelial cells (HUVEC).	Methoxsalen	139-156	vascular cell adhesion molecule 1	Homo sapiens	318-355
8628215-2	1996	Induction of SNM1-lacZ fusions was detected in response to nitrogen mustard, cis-platinum (II) diamine dichloride, UV light, and 8-methoxypsoralen + UVA, but not after heat-shock treatment or incubation with 2-dimethylaminoethylchloride, methylmethane sulfonate or 4-nitroquinoline-N-oxide.	Methoxsalen	129-146	Snm1p	Saccharomyces cerevisiae S288C	13-17
8967376-2	1996	Pretreatment with the cytochrome P-450 inhibitor 8-methoxypsoralen prevented the ECV-induced increase in venous admixture but not the increased EVLW.	Methoxsalen	49-66	Cytochrome P450 1A1	Canis lupus familiaris	22-38
8596155-1	1995	OBJECTIVE: Having previously found that treating small areas of synovitis within the knees of patients with rheumatoid arthritis (RA) with 8-methoxypsoralen (8-MOP) and laser-derived ultraviolet A (PUVA) resulted in decreases in adhesion molecule expression, we sought to determine the effect of PUVA on expression of vascular cellular adhesion molecule 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), and E-selection by human umbilical vein endothelial cells (HUVEC).	Methoxsalen	139-156	vascular cell adhesion molecule 1	Homo sapiens	357-363
8596155-1	1995	OBJECTIVE: Having previously found that treating small areas of synovitis within the knees of patients with rheumatoid arthritis (RA) with 8-methoxypsoralen (8-MOP) and laser-derived ultraviolet A (PUVA) resulted in decreases in adhesion molecule expression, we sought to determine the effect of PUVA on expression of vascular cellular adhesion molecule 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), and E-selection by human umbilical vein endothelial cells (HUVEC).	Methoxsalen	139-156	intercellular adhesion molecule 1	Homo sapiens	366-399
8596155-1	1995	OBJECTIVE: Having previously found that treating small areas of synovitis within the knees of patients with rheumatoid arthritis (RA) with 8-methoxypsoralen (8-MOP) and laser-derived ultraviolet A (PUVA) resulted in decreases in adhesion molecule expression, we sought to determine the effect of PUVA on expression of vascular cellular adhesion molecule 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), and E-selection by human umbilical vein endothelial cells (HUVEC).	Methoxsalen	139-156	intercellular adhesion molecule 1	Homo sapiens	401-407
7788855-0	1995	Mutagenicity and specific mutation spectrum induced by 8-methoxypsoralen plus a low dose of UVA in the hprt gene in diploid human fibroblasts.	Methoxsalen	55-72	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	103-107
10155561-2	1994	Several independent and multicenter trials using lymphapheresis with 8-methoxypsoralen (8-MOP) activated by shortwave ultraviolet light have demonstrated the clinical benefit of this modality for treatment of advanced CTCL.	Methoxsalen	69-86	TSPY like 2	Homo sapiens	218-222
7702611-0	1995	Suppression of cytochrome P450 (Cyp1a-1) induction in mouse hepatoma Hepa-1C1C7 cells by methoxsalen.	Methoxsalen	89-100	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	32-39
7702611-1	1995	Cultured mouse hepatoma cell line Hepa-1c1c7 cells were treated with methoxsalen to assess the role of methoxsalen in the process of Cyp1a-1 induction.	Methoxsalen	103-114	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	133-140
7702611-4	1995	We find that treatment of Hepa-1c1c7 cells with methoxsalen inhibited CYP1A1 mRNA induction by TCDD as well as the concomitant increase P4501A1 protein.	Methoxsalen	48-59	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	70-76
7702611-5	1995	Formation of DNA-protein complexes between the dioxin receptor and its DRE target was inhibited by methoxsalen, as determined by gel mobility shift assays using oligonucleotides corresponding to DRE 3 of the Cyp1a-1 gene.	Methoxsalen	99-110	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	208-215
7702611-6	1995	These results suggest that the inhibitory action of methoxsalen on TCDD induction of the Cyp1a-1 gene expression in Hepa-1c1c7 cells might be antagonism of the DNA binding potential of nuclear dioxin receptor.	Methoxsalen	52-63	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	89-96
8534123-1	1995	Extracorporeal photopheresis (ECP) using UVA irradiation of enriched lymphocytes in the presence of 8-methoxypsoralen as a photoactivatable substrate was originally introduced as a therapeutic regimen for cutaneous T-cell lymphoma (CTCL).	Methoxsalen	100-117	TSPY like 2	Homo sapiens	232-236
7712112-2	1994	Treatment with inhibitors of hepatic cytochrome P-450-dependent monooxygenases such as carbon disulfide, methoxsalen, piperonyl butoxide, and SKF-525A prevented or tended to reduce the hepatotoxic effect of styrene given in combination with BSO.	Methoxsalen	105-116	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	37-53
10155561-2	1994	Several independent and multicenter trials using lymphapheresis with 8-methoxypsoralen (8-MOP) activated by shortwave ultraviolet light have demonstrated the clinical benefit of this modality for treatment of advanced CTCL.	Methoxsalen	88-93	TSPY like 2	Homo sapiens	218-222
7945434-1	1994	Methoxsalen (8-methoxypsoralen) is a very potent inhibitor of human cytochrome P450 2A6 (CYP2A6) and mouse Cyp2a-5-mediated coumarin 7-hydroxylation in vitro.	Methoxsalen	0-11	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	68-87
7945434-8	1994	In pyrazole-induced mouse liver microsomes, methoxsalen metabolism was inhibited by the anti-Cyp2a-5 antibody.	Methoxsalen	44-55	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	93-100
7945434-1	1994	Methoxsalen (8-methoxypsoralen) is a very potent inhibitor of human cytochrome P450 2A6 (CYP2A6) and mouse Cyp2a-5-mediated coumarin 7-hydroxylation in vitro.	Methoxsalen	0-11	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	89-95
7945434-9	1994	Cyp2a-5 protein expressed in the yeast Saccharomyces cerevisiae was capable of metabolizing methoxsalen, indicating that methoxsalen is a substrate of Cyp2a-5.	Methoxsalen	92-103	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	0-7
7945434-1	1994	Methoxsalen (8-methoxypsoralen) is a very potent inhibitor of human cytochrome P450 2A6 (CYP2A6) and mouse Cyp2a-5-mediated coumarin 7-hydroxylation in vitro.	Methoxsalen	0-11	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	107-114
7945434-9	1994	Cyp2a-5 protein expressed in the yeast Saccharomyces cerevisiae was capable of metabolizing methoxsalen, indicating that methoxsalen is a substrate of Cyp2a-5.	Methoxsalen	92-103	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	151-158
7945434-9	1994	Cyp2a-5 protein expressed in the yeast Saccharomyces cerevisiae was capable of metabolizing methoxsalen, indicating that methoxsalen is a substrate of Cyp2a-5.	Methoxsalen	121-132	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	0-7
7945434-9	1994	Cyp2a-5 protein expressed in the yeast Saccharomyces cerevisiae was capable of metabolizing methoxsalen, indicating that methoxsalen is a substrate of Cyp2a-5.	Methoxsalen	121-132	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	151-158
7945434-1	1994	Methoxsalen (8-methoxypsoralen) is a very potent inhibitor of human cytochrome P450 2A6 (CYP2A6) and mouse Cyp2a-5-mediated coumarin 7-hydroxylation in vitro.	Methoxsalen	13-30	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	68-87
7945434-1	1994	Methoxsalen (8-methoxypsoralen) is a very potent inhibitor of human cytochrome P450 2A6 (CYP2A6) and mouse Cyp2a-5-mediated coumarin 7-hydroxylation in vitro.	Methoxsalen	13-30	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	89-95
7945434-1	1994	Methoxsalen (8-methoxypsoralen) is a very potent inhibitor of human cytochrome P450 2A6 (CYP2A6) and mouse Cyp2a-5-mediated coumarin 7-hydroxylation in vitro.	Methoxsalen	13-30	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	107-114
8313509-0	1994	Mutation specificity of 8-methoxypsoralen plus two doses of UVA irradiation in the hprt gene in diploid human fibroblasts.	Methoxsalen	24-41	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	83-87
8001161-0	1994	Heat shock changes the response of the pso3 mutant of Saccharomyces cerevisiae to 8-methoxypsoralen photoaddition.	Methoxsalen	82-99	ribonucleotide-diphosphate reductase subunit RNR4	Saccharomyces cerevisiae S288C	39-43
8463458-2	1993	During this procedure, the oral administration of the photoactive drug 8-methoxypsoralen (8-MOP) results in an unpredictable range of serum levels and in side effects limiting its efficacy.	Methoxsalen	71-88	opioid receptor mu 1	Homo sapiens	92-95
8461033-4	1993	The furanocoumarin derivatives methoxsalen (8-methoxypsoralen) and psoralen proved to be the most potent inhibitors of mouse COH activity (IC50 values 1.0 and 3.1 microM, respectively).	Methoxsalen	31-42	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	125-128
8461033-4	1993	The furanocoumarin derivatives methoxsalen (8-methoxypsoralen) and psoralen proved to be the most potent inhibitors of mouse COH activity (IC50 values 1.0 and 3.1 microM, respectively).	Methoxsalen	44-61	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	125-128
8461033-7	1993	Methoxsalen was a potent inhibitor of COH activity also in human liver microsomes, (IC50 value 5.4 microM), whereas bergapten, isopimpinellin and imperatorin had no effect.	Methoxsalen	0-11	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	38-41
8492245-7	1993	8-MOP photobinding to human serum albumin was also clearly inhibited (75-96%), but remarkably less to DNA (2-41%).	Methoxsalen	0-5	albumin	Homo sapiens	28-41
1378185-1	1992	The cloning rate of PHA-stimulated T lymphocytes after treatment with 8-methoxypsoralen plus UVA irradiation described by Wunder and Reischmann (1983) gives a linear dose-effect relationship at low dosages.	Methoxsalen	70-87	lamin B receptor	Homo sapiens	20-23
8440233-1	1993	We have determined the mutational specificity of 8-methoxypsoralen photoaddition at the endogenous adenine phosphoribosyltransferase gene of Chinese hamster ovary cells hemizygous for this locus.	Methoxsalen	49-66	adenine phosphoribosyltransferase	Cricetulus griseus	99-132
1497908-5	1992	The activity of cytochrome P-450IIB1, the major pulmonary cytochrome P-450 isozyme in rats, was clearly inhibited by 8-methoxypsoralen.	Methoxsalen	117-134	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	16-32
1432387-7	1992	Their photobiological properties, including erythema formation, reflect very closely those of 8-methoxypsoralen (8-MOP).	Methoxsalen	94-111	opioid receptor mu 1	Homo sapiens	115-118
1535214-6	1992	Treatment with 8-methoxypsoralen plus ultraviolet A radiation and treatment with triamcinolone acetonide both reduced the effect of retinoids on the production of bioactive IL-1.	Methoxsalen	15-32	interleukin 1 complex	Mus musculus	173-177
2045675-4	1991	On the other hand, if CsA was applied simultaneously with 3 J/cm2 UV-A 1 h after treatment with 0.3% 8-methoxypsoralen, PUVA-induced ODC activity was suppressed by about 60% at 12 and 24 h after UV-A irradiation.	Methoxsalen	101-118	ornithine decarboxylase, structural 1	Mus musculus	133-136
1798746-0	1991	Structural elucidation of the 8-methoxypsoralen oxidized product that inhibits the chemotactic activity of polymorphonuclear neutrophils toward anaphylatoxin C5a.	Methoxsalen	30-47	complement C5a receptor 1	Homo sapiens	158-161
1798746-1	1991	The chemical structure of the 8-methoxypsoralen oxidized product that inhibits the chemotactic activity of anaphylatoxin C5a was determined to be 2,3-dihydro-2,9-dimethoxy-3-hydroxy-7-oxo-7H-furo[3,2-g] [1]benzopyran.	Methoxsalen	30-47	complement C5a receptor 1	Homo sapiens	121-124
1594941-1	1992	Treatment of an organism with UVB light or PUVA (8-methoxypsoralen + UVA light) not only leads to alterations in the irradiated skin but also to systemic immunomodulation, due to the release of several chemical mediators of immunosuppression like prostaglandins, acute-phase proteins, IL-1 inhibitor, alpha-melanocyte-stimulating hormone, propiomelanocorticotropin or other cytokines.	Methoxsalen	49-66	interleukin 1 receptor antagonist	Mus musculus	285-299
1594941-1	1992	Treatment of an organism with UVB light or PUVA (8-methoxypsoralen + UVA light) not only leads to alterations in the irradiated skin but also to systemic immunomodulation, due to the release of several chemical mediators of immunosuppression like prostaglandins, acute-phase proteins, IL-1 inhibitor, alpha-melanocyte-stimulating hormone, propiomelanocorticotropin or other cytokines.	Methoxsalen	49-66	pro-opiomelanocortin-alpha	Mus musculus	301-337
1376436-3	1992	In FA complementation group A (FA-A) cells, one endonuclease activity, pI 4.6, which recognizes psoralen intercalation and interstrand cross-links, has 25% of the activity of the normal human endonuclease, pI 4.6, on 8-methoxypsoralen (8-MOP) plus UVA-damaged DNA.	Methoxsalen	217-234	FA complementation group A	Homo sapiens	31-35
1376436-3	1992	In FA complementation group A (FA-A) cells, one endonuclease activity, pI 4.6, which recognizes psoralen intercalation and interstrand cross-links, has 25% of the activity of the normal human endonuclease, pI 4.6, on 8-methoxypsoralen (8-MOP) plus UVA-damaged DNA.	Methoxsalen	236-241	FA complementation group A	Homo sapiens	31-35
1376436-4	1992	In FA complementation group B (FA-B) cells, a second endonuclease activity, pI 7.6, which recognizes psoralen monoadducts, has 50% and 55% of the activity, respectively, of the corresponding normal endonuclease on 8-MOP or angelicin plus UVA-damaged DNA.	Methoxsalen	214-219	FA complementation group B	Homo sapiens	3-29
1376436-4	1992	In FA complementation group B (FA-B) cells, a second endonuclease activity, pI 7.6, which recognizes psoralen monoadducts, has 50% and 55% of the activity, respectively, of the corresponding normal endonuclease on 8-MOP or angelicin plus UVA-damaged DNA.	Methoxsalen	214-219	FA complementation group B	Homo sapiens	31-35
1376436-7	1992	These deficiencies in two nuclear DNA endonuclease activities from FA-A and FA-B cells correlate with decreased levels of unscheduled DNA synthesis (UDS), in response to 8-MOP or angelicin plus UVA irradiation, in these cells in culture.	Methoxsalen	170-175	FA complementation group A	Homo sapiens	67-71
1376436-7	1992	These deficiencies in two nuclear DNA endonuclease activities from FA-A and FA-B cells correlate with decreased levels of unscheduled DNA synthesis (UDS), in response to 8-MOP or angelicin plus UVA irradiation, in these cells in culture.	Methoxsalen	170-175	FA complementation group B	Homo sapiens	76-80
2025880-3	1991	The role of cytochrome P-450 in the activation of 2-NP is indicated by the increase of liver DNA damage in rats pretreated with phenobarbital or beta-naphtoflavone, and by its reduction produced by methoxsalen.	Methoxsalen	198-209	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	12-28
2117068-4	1990	A monoclonal antibody (MAb 1-7-1), which recognizes isozymes of cytochrome P-450 induced by 3-methylcholanthrene (P1-450 and P3-450), selectively inhibited the metabolism of 8-MOP (-57%) and covalent binding of its metabolites (-40%) in microsomes from mice pretreated with BNF, but had no effect in microsomes of mice pretreated with phenobarbital or vehicle.	Methoxsalen	174-179	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	64-80
1914077-1	1991	Treatment of peripheral blood mononuclear cells with 8-methoxypsoralen (8-MOP) and ultraviolet light, a procedure known as PUVA, has been found to be useful in the management of systemically disseminated cutaneous T-cell lymphoma (CTCL).	Methoxsalen	53-70	TSPY like 2	Homo sapiens	231-235
1914077-1	1991	Treatment of peripheral blood mononuclear cells with 8-methoxypsoralen (8-MOP) and ultraviolet light, a procedure known as PUVA, has been found to be useful in the management of systemically disseminated cutaneous T-cell lymphoma (CTCL).	Methoxsalen	72-77	TSPY like 2	Homo sapiens	231-235
2127639-1	1990	Psoralens (8-methoxypsoralen, 5-methoxypsoralen and 4,5,8-trimethylpsoralen) stimulate mouse melanoma cell (S91 and B16/F10) tyrosinase activity in vitro in a dose-related manner.	Methoxsalen	11-28	tyrosinase	Mus musculus	125-135
1857746-0	1991	Inhibitory effect of 8-methoxypsoralen plus ultraviolet-A on interleukin-1 production by murine keratinocytes.	Methoxsalen	21-38	interleukin 1 complex	Mus musculus	61-74
1857746-1	1991	We report the effects of 8-methoxypsoralen (8-MOP) plus ultraviolet-A (UV-A) irradiation on interleukin-1 (IL-1) production by murine epidermal keratinocytes, correlating its effect on IL-1 with cell viability, DNA synthesis, and 8-MOP-DNA photoadduct formation.	Methoxsalen	25-42	interleukin 1 complex	Mus musculus	92-105
1857746-1	1991	We report the effects of 8-methoxypsoralen (8-MOP) plus ultraviolet-A (UV-A) irradiation on interleukin-1 (IL-1) production by murine epidermal keratinocytes, correlating its effect on IL-1 with cell viability, DNA synthesis, and 8-MOP-DNA photoadduct formation.	Methoxsalen	25-42	interleukin 1 complex	Mus musculus	107-111
1857746-1	1991	We report the effects of 8-methoxypsoralen (8-MOP) plus ultraviolet-A (UV-A) irradiation on interleukin-1 (IL-1) production by murine epidermal keratinocytes, correlating its effect on IL-1 with cell viability, DNA synthesis, and 8-MOP-DNA photoadduct formation.	Methoxsalen	25-42	interleukin 1 complex	Mus musculus	185-189
1857746-4	1991	Interleukin-1 inhibitors induced by 8-MOP plus UV-A were not detected in either supernatant or cell extract.	Methoxsalen	36-41	interleukin 1 complex	Mus musculus	0-13
1676067-2	1991	8-MOP (1 microgram mL-1) increased [3H]TdR incorporation and caused a rise in the blastic and mitotic index in all experimental cultures.	Methoxsalen	0-5	L1 cell adhesion molecule	Mus musculus	19-23
2117068-5	1990	Monoclonal antibody 2-66-3, which recognizes the major isozymes of rat cytochrome P-450 induced by phenobarbital and unknown isozymes in the mouse, enhanced the covalent binding of 8-MOP metabolites in microsomes of mice pretreated with vehicle (+74%), phenobarbital (+44%) or BNF (+31%) without affecting the disappearance of 8-MOP.	Methoxsalen	181-186	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	71-87
2117068-5	1990	Monoclonal antibody 2-66-3, which recognizes the major isozymes of rat cytochrome P-450 induced by phenobarbital and unknown isozymes in the mouse, enhanced the covalent binding of 8-MOP metabolites in microsomes of mice pretreated with vehicle (+74%), phenobarbital (+44%) or BNF (+31%) without affecting the disappearance of 8-MOP.	Methoxsalen	327-332	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	71-87
34883035-9	2022	In ex vivo skin permeation, nanoemulgel (NG2) showed increased penetration and localized accumulation of methoxsalen across the skin compared with plain gel.	Methoxsalen	105-116	chondroitin sulfate proteoglycan 4	Homo sapiens	41-44
2227048-0	1990	[8-MOP serum level profile following administration of Geroxalen to patients with psoriasis and a control group].	Methoxsalen	55-64	opioid receptor mu 1	Homo sapiens	3-6
2227048-1	1990	UNLABELLED: After 8-MOP application (Geroxalen) the mean serum levels with 11 single values over 8 hours from 21 psoriatics with squamous infiltrative plaques do not differ from serum level curves of 46 healthy volunteers (Psoriatics: maximum plasma level cmax 189 nm 8 MOP/ml serum at the time tmax 1,2h; area under the curve AUC0-8 284 ng.ml-1.h.	Methoxsalen	37-46	opioid receptor mu 1	Homo sapiens	20-23
26121067-0	2015	8-methoxypsoralen plus UVA (PUVA) therapy normalizes signalling of phosphorylated component of mTOR pathway in psoriatic skin of K5.hTGFbeta1 transgenic mice.	Methoxsalen	0-17	mechanistic target of rapamycin kinase	Mus musculus	95-99
26121067-0	2015	8-methoxypsoralen plus UVA (PUVA) therapy normalizes signalling of phosphorylated component of mTOR pathway in psoriatic skin of K5.hTGFbeta1 transgenic mice.	Methoxsalen	0-17	transforming growth factor beta 1	Homo sapiens	132-141
12695782-0	1989	Toxicology and Carcinogenesis Studies of 8-Methoxypsoralen (CAS No.	Methoxsalen	41-58	BCAR1 scaffold protein, Cas family member	Rattus norvegicus	60-63
35164207-7	2022	Xanthotoxin induced significant increase in Annexin-V-positive HepG2 cells both at the early and late stages of apoptosis, as well as a significant decrease in autophagic flux in cancer compared with control cells.	Methoxsalen	0-11	annexin A5	Homo sapiens	44-53
34552480-0	2021	8-Methoxypsoralen has Anti-inflammatory and Antioxidant Roles in Osteoarthritis Through SIRT1/NF-kappaB Pathway.	Methoxsalen	0-17	sirtuin 1	Rattus norvegicus	88-93
34552480-7	2021	Our results revealed that 8-MOP evidently reduced IL-1beta-mediated apoptosis and inhibition of proliferation, and mitigated the expression of inflammatory cytokines and oxidative stress factors in chondrocytes.	Methoxsalen	26-31	interleukin 1 alpha	Rattus norvegicus	50-58
34552480-8	2021	Additionally, 8-MOP promoted phosphorylated level of AMPKalpha, enhanced SIRT1 expression and inhibited the phosphorylation of NF-kappaB.	Methoxsalen	14-19	sirtuin 1	Rattus norvegicus	73-78
34552480-11	2021	In addition, 8-MOP relieved inflammatory and oxidative stress responses in the articular cartilage via enhancing SIRT1 and repressing NF-kappaB activation.	Methoxsalen	13-18	sirtuin 1	Rattus norvegicus	113-118
34552480-13	2021	In summary, our study testified that 8-MOP alleviates pain, inflammatory and oxidative stress responses in OA rats through the SIRT1/NF-kappaB pathway, which is expected to become a new reagent for clinical treatment of OA.	Methoxsalen	37-42	sirtuin 1	Rattus norvegicus	127-132
2506333-0	1989	Suicide inactivation of cytochrome P-450 by methoxsalen.	Methoxsalen	44-55	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	24-40
2506333-2	1989	Incubation of rat liver microsomes with [3H]methoxsalen and NADPH resulted in the covalent binding of a methoxsalen intermediate to proteins comigrating with cytochromes P-450 UT-A, PB-B/D, ISF-G and PCN-E.	Methoxsalen	44-55	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	170-180
2506333-8	1989	Whereas methoxsalen itself did not produce any binding spectrum, in contrast either in vivo administration of methoxsalen or incubation in vitro with methoxsalen and NADPH resulted in a low-to-high spin conversion of cytochrome P-450 as suggested by the appearance of a spectrum analogous to a type I binding spectrum.	Methoxsalen	110-121	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	217-233
2506333-8	1989	Whereas methoxsalen itself did not produce any binding spectrum, in contrast either in vivo administration of methoxsalen or incubation in vitro with methoxsalen and NADPH resulted in a low-to-high spin conversion of cytochrome P-450 as suggested by the appearance of a spectrum analogous to a type I binding spectrum.	Methoxsalen	110-121	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	217-233
2506333-10	1989	We conclude that suicide inactivation of cytochrome P-450 by methoxsalen is related to the covalent binding of a methoxsalen intermediate to the protein moiety of several cytochrome P-450 isoenzymes (including UT-A, PB-B/D, PCN-E as well as ISF-G and/or beta NF-B).	Methoxsalen	61-72	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	41-57
2506333-10	1989	We conclude that suicide inactivation of cytochrome P-450 by methoxsalen is related to the covalent binding of a methoxsalen intermediate to the protein moiety of several cytochrome P-450 isoenzymes (including UT-A, PB-B/D, PCN-E as well as ISF-G and/or beta NF-B).	Methoxsalen	61-72	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	171-187
2506333-10	1989	We conclude that suicide inactivation of cytochrome P-450 by methoxsalen is related to the covalent binding of a methoxsalen intermediate to the protein moiety of several cytochrome P-450 isoenzymes (including UT-A, PB-B/D, PCN-E as well as ISF-G and/or beta NF-B).	Methoxsalen	113-124	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	41-57
2506333-10	1989	We conclude that suicide inactivation of cytochrome P-450 by methoxsalen is related to the covalent binding of a methoxsalen intermediate to the protein moiety of several cytochrome P-450 isoenzymes (including UT-A, PB-B/D, PCN-E as well as ISF-G and/or beta NF-B).	Methoxsalen	113-124	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	171-187
2544311-1	1989	A study of the repair of DNA damage in the dihydrofolate reductase (dhfr) gene of SV40-transformed human fibroblasts after treatment with 8-methoxypsoralen (8MOP) and UVA is described.	Methoxsalen	138-155	dihydrofolate reductase	Homo sapiens	43-66
2544311-1	1989	A study of the repair of DNA damage in the dihydrofolate reductase (dhfr) gene of SV40-transformed human fibroblasts after treatment with 8-methoxypsoralen (8MOP) and UVA is described.	Methoxsalen	138-155	dihydrofolate reductase	Homo sapiens	68-72
2585773-3	1989	CTCL patients were treated by photochemotherapy with topical 8-methoxypsoralen (8-MOP) followed by VUA irradiation, electron-beam irradiation, or systemic chemotherapy.	Methoxsalen	61-78	TSPY like 2	Homo sapiens	0-4
2730678-0	1989	Activation of 8-methoxypsoralen by cytochrome P-450.	Methoxsalen	14-31	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	35-51
2730678-12	1989	Collectively, these results indicate that 8-MOP is biotransformed by two or more isozymes of cytochrome P-450 to reactive electrophiles capable of binding to tissue macromolecules.	Methoxsalen	42-47	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	93-109
2585773-3	1989	CTCL patients were treated by photochemotherapy with topical 8-methoxypsoralen (8-MOP) followed by VUA irradiation, electron-beam irradiation, or systemic chemotherapy.	Methoxsalen	80-85	TSPY like 2	Homo sapiens	0-4
2462418-0	1988	Effects of 8-methoxypsoralen and ultraviolet light A on EGF receptor (HER-1) expression.	Methoxsalen	11-28	epidermal growth factor receptor	Homo sapiens	70-75
2703963-8	1989	Several cytochrome P-450 inhibitors [metyrapone, 8-methoxypsoralen, 2-(4,6-dichloro-biphenyloxy) ethylamine, alpha-naphthoflavone and cimetidine] decreased the biliary excretion of AA-GS, although SKF 525-A and piperonyl butoxide did not.	Methoxsalen	49-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-24
2462418-3	1988	In view of these findings, we have examined whether 8-methoxy-psoralen (8-MOP) itself, or in combination with UVA, influences expression of the human EGF-receptor gene ("HER-1") in a human keratinocyte cell line.	Methoxsalen	52-70	epidermal growth factor receptor	Homo sapiens	170-176
2462418-3	1988	In view of these findings, we have examined whether 8-methoxy-psoralen (8-MOP) itself, or in combination with UVA, influences expression of the human EGF-receptor gene ("HER-1") in a human keratinocyte cell line.	Methoxsalen	72-77	epidermal growth factor receptor	Homo sapiens	170-176
2462418-5	1988	The combination of 8-MOP with UVA produces less induction of HER-1 RNA than that obtained with 8-MOP alone.	Methoxsalen	19-24	epidermal growth factor receptor	Homo sapiens	61-66
3150000-1	1988	The relative affinity of 5-methoxypsoralen (5-MOP) and 8-methoxypsoralen (8-MOP) towards beta-cyclodextrin, a good model for the study of lipophilic interactions in biological systems and a potential drug carrier, has been investigated using spectroscopic and chromatographic methods.	Methoxsalen	55-72	opioid receptor mu 1	Homo sapiens	76-79
3319774-0	1987	[Repair of plasmid DNA treated with 8-methoxypsoralen and long-wave UV light (lambda=365 nm) in wild type and mutant rad2 cells of Saccharomyces cerevisiae].	Methoxsalen	36-53	ssDNA endodeoxyribonuclease RAD2	Saccharomyces cerevisiae S288C	117-121
3264275-3	1988	At the optimal concentration of PHA, 8-MOP (140 microM) caused a delay in lymphocyte proliferation, interleukin-2 (IL-2) production/accumulation and IL-2 receptor expression.	Methoxsalen	37-42	interleukin 2	Homo sapiens	115-119
3264275-3	1988	At the optimal concentration of PHA, 8-MOP (140 microM) caused a delay in lymphocyte proliferation, interleukin-2 (IL-2) production/accumulation and IL-2 receptor expression.	Methoxsalen	37-42	interleukin 2 receptor subunit beta	Homo sapiens	149-162
3264275-5	1988	At the suboptimal concentration of PHA, 8-MOP (140 microM) caused a sustained inhibition of lymphocyte proliferation, IL-2 production/accumulation and IL-2 receptor expression.	Methoxsalen	40-45	interleukin 2	Homo sapiens	118-122
3264275-5	1988	At the suboptimal concentration of PHA, 8-MOP (140 microM) caused a sustained inhibition of lymphocyte proliferation, IL-2 production/accumulation and IL-2 receptor expression.	Methoxsalen	40-45	interleukin 2 receptor subunit beta	Homo sapiens	151-164
2968374-4	1988	The average minimal phototoxic ultraviolet A (UVA) dose (MPD) obtained after 15 minutes" bathing was 0.86 joule/cm2 for trioxsalen and 9.76 joules/cm2 for methoxsalen.	Methoxsalen	155-166	mevalonate diphosphate decarboxylase	Homo sapiens	57-60
3058601-1	1988	8-Methoxypsoralen (8-MOP) is a photoactivated drug used clinically in the treatment of psoriasis and cutaneous T-cell lymphoma (CTCL).	Methoxsalen	0-17	TSPY like 2	Homo sapiens	128-132
3058601-1	1988	8-Methoxypsoralen (8-MOP) is a photoactivated drug used clinically in the treatment of psoriasis and cutaneous T-cell lymphoma (CTCL).	Methoxsalen	19-24	TSPY like 2	Homo sapiens	128-132
3264275-3	1988	At the optimal concentration of PHA, 8-MOP (140 microM) caused a delay in lymphocyte proliferation, interleukin-2 (IL-2) production/accumulation and IL-2 receptor expression.	Methoxsalen	37-42	interleukin 2	Homo sapiens	100-113
3690940-10	1987	Other work has shown that inhibition of drug metabolism by methoxsalen is associated with both extensive covalent binding of metabolite(s) of methoxsalen to liver microsomal protein in vitro and in vivo and inactivation of cytochrome P-450.	Methoxsalen	59-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	223-239
3496400-5	1987	Interleukin 2 production was impaired in cells from PUVA-treated mice compared with those from UVA-irradiated, 8-methoxypsoralen-treated, or normal mice.	Methoxsalen	111-128	interleukin 2	Mus musculus	0-13
3105541-0	1987	The drug methoxsalen, a suicide substrate for cytochrome P-450, decreases the metabolic activation, and prevents the hepatotoxicity, of carbon tetrachloride in mice.	Methoxsalen	9-20	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	46-62
3494453-0	1987	Inactivation of human liver cytochrome P-450 by the drug methoxsalen and other psoralen derivatives.	Methoxsalen	57-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-44
3494453-2	1987	CO-binding cytochrome P-450 was decreased by 33% after 10 min of incubation with 1.5 mM EDTA, an NADPH-regenerating system and 20 microM methoxsalen (8-methoxypsoralen).	Methoxsalen	137-148	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-27
3494453-2	1987	CO-binding cytochrome P-450 was decreased by 33% after 10 min of incubation with 1.5 mM EDTA, an NADPH-regenerating system and 20 microM methoxsalen (8-methoxypsoralen).	Methoxsalen	150-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-27
3494453-9	1987	We conclude that methoxsalen is an extremely potent suicide inhibitor of cytochrome P-450 in human liver microsomes.	Methoxsalen	17-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-89
3105541-1	1987	Methoxsalen, a potent suicide inhibitor of cytochrome P-450 that can be used in humans, might be of value for the prevention of hepatitis in subjects with carbon tetrachloride poisoning.	Methoxsalen	0-11	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	43-59
6531023-2	1984	The most widely used compound is 8-methoxypsoralen (8-MOP); its effectiveness has been documented by many clinical trials.	Methoxsalen	33-50	opioid receptor mu 1	Homo sapiens	54-57
3582276-3	1987	By 4 h into the dark period (at 2400 h), the NAT activity in both 8-MOP injected groups of rats was greater than that in vehicle treated animals; again, however, 8-MOP treatment did not influence the pineal melatonin content.	Methoxsalen	66-71	N-acetyltransferase 1	Rattus norvegicus	45-48
3582276-4	1987	At 0200 h (6 h into the dark period), the difference between the NAT activity in pineals of rats treated with 5 mg/kg 8-MOP and the vehicle was not statistically significant, but the animals that received 10 mg/kg drug still had statistically elevated levels of the serotonin acetylating enzyme.	Methoxsalen	118-123	N-acetyltransferase 1	Rattus norvegicus	65-68
3582276-6	1987	Rats given 5mg/kg 8-MOP always had NAT values intermediate between those of rats injected with vehicle and those that received 10 mg/kg 8-MOP suggesting that the NAT response to the drug was dose related.	Methoxsalen	18-23	N-acetyltransferase 1	Rattus norvegicus	35-38
3582276-6	1987	Rats given 5mg/kg 8-MOP always had NAT values intermediate between those of rats injected with vehicle and those that received 10 mg/kg 8-MOP suggesting that the NAT response to the drug was dose related.	Methoxsalen	18-23	N-acetyltransferase 1	Rattus norvegicus	162-165
3114156-5	1987	The observed decrease in lymphocyte proliferation hyporesponsiveness to interleukin-2 correlated with the ability of 8-methoxypsoralen to induce a dose-dependent decrease in interleukin-2 receptor expression on phytohemagglutinin-stimulated lymphocytes.	Methoxsalen	117-134	interleukin 2	Homo sapiens	72-85
3114156-5	1987	The observed decrease in lymphocyte proliferation hyporesponsiveness to interleukin-2 correlated with the ability of 8-methoxypsoralen to induce a dose-dependent decrease in interleukin-2 receptor expression on phytohemagglutinin-stimulated lymphocytes.	Methoxsalen	117-134	interleukin 2	Homo sapiens	174-187
3114156-6	1987	Since interleukin-2 receptors play a central role in lymphocyte proliferation and immune reactivity, their decrease may explain the mechanism by which 8-methoxypsoralen impairs lymphocyte function.	Methoxsalen	151-168	interleukin 2	Homo sapiens	6-19
3772810-1	1986	We have reported previously that methoxsalen is a suicide substrate for cytochrome P-450.	Methoxsalen	33-44	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	72-88
3016102-3	1986	Utilizing a CaM-activated phosphodiesterase we have demonstrated that even at very high concentrations, the systemic drugs etretinate, methotrexate, and 8-methoxypsoralen, and the topical agents hydrocortisone and crude coal tar showed minimal CaM inhibitory activity.	Methoxsalen	153-170	calmodulin 1	Homo sapiens	12-15
3735138-3	1986	CO-binding cytochrome P-450 decreased when hepatic microsomes were incubated for 10 min with an NADPH-generating system and 8-methoxypsoralen, 5-methoxypsoralen or psoralen (400 microM), but remained unchanged with trioxsalen (400 microM).	Methoxsalen	124-141	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	11-27
3941395-9	1986	We conclude that methoxsalen is activated into a metabolite which destroys cytochrome P-450.	Methoxsalen	17-28	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	75-91
4084591-0	1985	NMR study of the drug-base overlap geometry in the dark complex of 8-methoxypsoralen and d(pApT)4.	Methoxsalen	67-84	poly(A) polymerase beta	Homo sapiens	91-95
4084591-1	1985	The dark binding of 8-methoxypsoralen (MOP) to d(pApT)4 was investigated by 270-MHz 1H nuclear magnetic resonance (NMR) spectra.	Methoxsalen	20-37	poly(A) polymerase beta	Homo sapiens	49-53
4084591-1	1985	The dark binding of 8-methoxypsoralen (MOP) to d(pApT)4 was investigated by 270-MHz 1H nuclear magnetic resonance (NMR) spectra.	Methoxsalen	39-42	poly(A) polymerase beta	Homo sapiens	49-53
2993427-2	1985	In the absence of ultraviolet A radiation, 8-MOP and TMP caused an increase in the concentration of cAMP, but not cyclic GMP, in all of these cells.	Methoxsalen	43-48	5'-nucleotidase, cytosolic II	Homo sapiens	121-124
3491788-4	1986	The main cis-syn diastereoisomeric [2+2] photocycloadducts which arise from the photoreaction of 8-methoxypsoralen and thymidine in frozen aqueous solutions were shown to involve either the 4",5" furan ring or the 3,4 pyrone moiety and the 5,6-pyrimidine bond.	Methoxsalen	97-114	synemin	Homo sapiens	13-16
3941395-0	1986	Inactivation of cytochrome P-450 by the drug methoxsalen.	Methoxsalen	45-56	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	16-32
3941395-4	1986	Methoxsalen (25-1000 microM) decreased cytochrome P-450 in vitro, in the presence of EDTA; this effect required NADPH and oxygen, was decreased by piperonyl butoxide and was increased by phenobarbital pretreatment.	Methoxsalen	0-11	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	39-55
6531043-9	1984	Chronic administration of 8-MOP to Skh:hairless-1 mice caused significant enhancement of hepatic ethylmorphine N-demethylase and cytochrome P-450 but had no effect on AHH, whereas chronically administered TMP had no significant effect on any of these parameters.	Methoxsalen	26-31	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	129-145
6237155-6	1984	The phenotype of suppressor cells induced in mice treated once with 8-methoxypsoralen plus UVA (320 to 400 nm) radiation, followed by painting unexposed skin with oxazalone, was Lyt-1+2+, suggesting that this treatment may activate a different suppressor pathway.	Methoxsalen	68-85	CD5 antigen	Mus musculus	178-183
6600397-1	1983	Inhibition by sunscreens of UV-A-induced epidermal ornithine decarboxylase (ODC) activity in 8-methoxypsoralen-treated mice was used to examine the UV-A sunscreen activity of two commercial preparations, Uval (para-aminobenzoic acid) and PreSun (a benzophenone derivative).	Methoxsalen	93-110	ornithine decarboxylase, structural 1	Mus musculus	51-74
6616056-1	1983	Photosensitized luminescence of singlet (1 delta g) molecular oxygen with the maximum at 1272 nm has been found in solutions of psoralen, angelicin and 8-methoxypsoralen in CCl4.	Methoxsalen	152-169	C-C motif chemokine ligand 4	Homo sapiens	173-177
6849820-1	1983	Hairless albino mice have been treated with topically applied 8-methoxypsoralen and 5-methoxypsoralen at two concentrations and exposed to solar simulated radiation.	Methoxsalen	62-79	lysine demethylase and nuclear receptor corepressor	Mus musculus	0-8
6609177-2	1984	In 1975 we started a prospective study on oral methoxsalen photochemotherapy (PUVA) in cutaneous T cell lymphoma (CTCL).	Methoxsalen	47-58	TSPY like 2	Homo sapiens	114-118
6600397-1	1983	Inhibition by sunscreens of UV-A-induced epidermal ornithine decarboxylase (ODC) activity in 8-methoxypsoralen-treated mice was used to examine the UV-A sunscreen activity of two commercial preparations, Uval (para-aminobenzoic acid) and PreSun (a benzophenone derivative).	Methoxsalen	93-110	ornithine decarboxylase, structural 1	Mus musculus	76-79
7108267-3	1982	8-MOP administered orally to CD-1 mice daily for 6 days caused 2-3 fold increases in hepatic aryl hydrocarbon hydroxylase (AHH), ethylmorphine N-demethylase and cytochrome P-450.	Methoxsalen	0-5	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	93-121
7108267-3	1982	8-MOP administered orally to CD-1 mice daily for 6 days caused 2-3 fold increases in hepatic aryl hydrocarbon hydroxylase (AHH), ethylmorphine N-demethylase and cytochrome P-450.	Methoxsalen	0-5	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	123-126
7108267-3	1982	8-MOP administered orally to CD-1 mice daily for 6 days caused 2-3 fold increases in hepatic aryl hydrocarbon hydroxylase (AHH), ethylmorphine N-demethylase and cytochrome P-450.	Methoxsalen	0-5	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	161-177
7108267-6	1982	Chronic administration of 8-MOP to hairless mice caused significant enhancement of hepatic ethylmorphine N-demethylase and cytochrome P-450 but had no effect on AHH; whereas chronically administered TMP had no significant effect on any of these parameters.	Methoxsalen	26-31	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	123-139
7108267-8	1982	8-MOP administered daily for 6 days to rats caused a greater than 4-fold enhancement of AHH and greater than 2-fold enhancement of ethylmorphine N-demethylase and cytochrome P-450.	Methoxsalen	0-5	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	88-91
7108267-8	1982	8-MOP administered daily for 6 days to rats caused a greater than 4-fold enhancement of AHH and greater than 2-fold enhancement of ethylmorphine N-demethylase and cytochrome P-450.	Methoxsalen	0-5	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	163-179
7108267-9	1982	These studies indicate that orally administered 8-MOP induces hepatic drug-metabolizing enzymes and cytochrome P-450 to a lesser extent than do the barbituates and suggest that this drug could influence the rate of biotransformation of concomitantly administered drugs in patients undergoing PUVA therapy.	Methoxsalen	48-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-116
7096664-5	1982	Increased epidermal ODC activity has been reported after exposure to UVB radiation (290-320 nm) alone and with topical 8-methoxypsoralen (8-MOP) plus UVA radiation.	Methoxsalen	119-136	ornithine decarboxylase 1	Homo sapiens	20-23
7096664-5	1982	Increased epidermal ODC activity has been reported after exposure to UVB radiation (290-320 nm) alone and with topical 8-methoxypsoralen (8-MOP) plus UVA radiation.	Methoxsalen	138-143	ornithine decarboxylase 1	Homo sapiens	20-23
7037541-4	1982	The diploid of wild type and the diploid homozygous for the rad2 mutation (this mutation blocks the excision of UV-induced pyrimidine dimers) were more resistant to the lethal effect of 8-MOP plus 365 nm light than the haploid of wild type and rad2 haploid, respectively.	Methoxsalen	186-191	ssDNA endodeoxyribonuclease RAD2	Saccharomyces cerevisiae S288C	60-64
7037541-4	1982	The diploid of wild type and the diploid homozygous for the rad2 mutation (this mutation blocks the excision of UV-induced pyrimidine dimers) were more resistant to the lethal effect of 8-MOP plus 365 nm light than the haploid of wild type and rad2 haploid, respectively.	Methoxsalen	186-191	ssDNA endodeoxyribonuclease RAD2	Saccharomyces cerevisiae S288C	244-248
7165319-1	1982	: 8-Methoxypsoralen (8-MOP) in neuer galenischer Zubereitung und seine Beziehung zum 8-MOP-Serumspiegel.	Methoxsalen	2-19	opioid receptor mu 1	Homo sapiens	23-26
7165319-1	1982	: 8-Methoxypsoralen (8-MOP) in neuer galenischer Zubereitung und seine Beziehung zum 8-MOP-Serumspiegel.	Methoxsalen	2-19	opioid receptor mu 1	Homo sapiens	87-90
7165319-2	1982	8-Methoxypsoralen (8-MOP)--a new galenic form and its relation to 8-MOP serum levels.	Methoxsalen	0-17	opioid receptor mu 1	Homo sapiens	21-24
7165319-2	1982	8-Methoxypsoralen (8-MOP)--a new galenic form and its relation to 8-MOP serum levels.	Methoxsalen	0-17	opioid receptor mu 1	Homo sapiens	68-71
6996774-4	1980	Based on data obtained on mammalian cells in culture a rad-equivalence could be estimated for the phototoxic effect (cell killing effect) of 8-methoxypsoralen used in PUVA-therapy.	Methoxsalen	141-158	RRAD, Ras related glycolysis inhibitor and calcium channel regulator	Homo sapiens	55-58
7026532-3	1981	For 8-methoxypsoralen photoaddition, which induces both deoxyribonucleic acid interstrand cross-links and monoadditions, the pso1 mutation is epistatic to the rad6, rad52, and pso2 mutations, whereas it is synergistic to rad3.	Methoxsalen	4-21	DNA-directed DNA polymerase	Saccharomyces cerevisiae S288C	125-129
7026532-3	1981	For 8-methoxypsoralen photoaddition, which induces both deoxyribonucleic acid interstrand cross-links and monoadditions, the pso1 mutation is epistatic to the rad6, rad52, and pso2 mutations, whereas it is synergistic to rad3.	Methoxsalen	4-21	E2 ubiquitin-conjugating protein RAD6	Saccharomyces cerevisiae S288C	159-163
7026532-3	1981	For 8-methoxypsoralen photoaddition, which induces both deoxyribonucleic acid interstrand cross-links and monoadditions, the pso1 mutation is epistatic to the rad6, rad52, and pso2 mutations, whereas it is synergistic to rad3.	Methoxsalen	4-21	recombinase RAD52	Saccharomyces cerevisiae S288C	165-170
7026532-3	1981	For 8-methoxypsoralen photoaddition, which induces both deoxyribonucleic acid interstrand cross-links and monoadditions, the pso1 mutation is epistatic to the rad6, rad52, and pso2 mutations, whereas it is synergistic to rad3.	Methoxsalen	4-21	DNA cross-link repair protein PSO2	Saccharomyces cerevisiae S288C	176-180
7026532-3	1981	For 8-methoxypsoralen photoaddition, which induces both deoxyribonucleic acid interstrand cross-links and monoadditions, the pso1 mutation is epistatic to the rad6, rad52, and pso2 mutations, whereas it is synergistic to rad3.	Methoxsalen	4-21	TFIIH/NER complex ATP-dependent 5'-3' DNA helicase subunit RAD3	Saccharomyces cerevisiae S288C	221-225
7252249-10	1981	Long-wave length ultraviolet alone produced no significant induction of ODC, however, certain phototoxic drugs (8-methoxypsoralen and anthracene) in combination with long-wave length ultraviolet did induce epidermal ODC.	Methoxsalen	112-129	ornithine decarboxylase 1	Homo sapiens	216-219
6267459-0	1981	Influence of mutations at the rep gene on survival of Escherichia coli following ultraviolet light irradiation or 8-methoxypsoralen photosensitization: evidence for a recA+ rep+-dependent pathway for repair of DNA crosslinks.	Methoxsalen	114-131	replication protein	Escherichia coli	30-33
6267459-6	1981	Rep- bacteria were rather more sensitive to the DNA cross-linking action f 8-methoxypsoralen (8-MOP) and NUV.	Methoxsalen	75-92	replication protein	Escherichia coli	0-3
6267459-6	1981	Rep- bacteria were rather more sensitive to the DNA cross-linking action f 8-methoxypsoralen (8-MOP) and NUV.	Methoxsalen	94-99	replication protein	Escherichia coli	0-3
6165204-1	1981	Itch was measured quantitatively as nocturnal scratch in 12 patients with psoriasis treated with 8-methoxypsoralen and UVA and in 7 treated with dithranol.	Methoxsalen	97-114	itchy E3 ubiquitin protein ligase	Homo sapiens	0-4
7294879-0	1981	[8-Methoxypsoralen (8-MOP)-a new galenic form and its relation to 8-MOP serum levels (author"s transl)].	Methoxsalen	1-18	opioid receptor mu 1	Homo sapiens	22-25
7294879-0	1981	[8-Methoxypsoralen (8-MOP)-a new galenic form and its relation to 8-MOP serum levels (author"s transl)].	Methoxsalen	1-18	opioid receptor mu 1	Homo sapiens	68-71
363510-1	1978	The method of repeated irradiation allowed to study kinetics of excision of mono-adducts induced by 8-methoxypsoralen (8-MOP) plus light (lambda=365 nm) in DNA of UV-sensitive mutants rad4 and rad15 and X-ray sensitive mutants rad54, xrs2, xrs4.	Methoxsalen	100-117	Rad4p	Saccharomyces cerevisiae S288C	184-188
363510-1	1978	The method of repeated irradiation allowed to study kinetics of excision of mono-adducts induced by 8-methoxypsoralen (8-MOP) plus light (lambda=365 nm) in DNA of UV-sensitive mutants rad4 and rad15 and X-ray sensitive mutants rad54, xrs2, xrs4.	Methoxsalen	119-124	DNA-dependent ATPase RAD54	Saccharomyces cerevisiae S288C	227-232
363510-1	1978	The method of repeated irradiation allowed to study kinetics of excision of mono-adducts induced by 8-methoxypsoralen (8-MOP) plus light (lambda=365 nm) in DNA of UV-sensitive mutants rad4 and rad15 and X-ray sensitive mutants rad54, xrs2, xrs4.	Methoxsalen	100-117	DNA-dependent ATPase RAD54	Saccharomyces cerevisiae S288C	227-232
363510-1	1978	The method of repeated irradiation allowed to study kinetics of excision of mono-adducts induced by 8-methoxypsoralen (8-MOP) plus light (lambda=365 nm) in DNA of UV-sensitive mutants rad4 and rad15 and X-ray sensitive mutants rad54, xrs2, xrs4.	Methoxsalen	119-124	Rad4p	Saccharomyces cerevisiae S288C	184-188
744263-0	1978	The binding of 8-methoxypsoralen by human serum albumin.	Methoxsalen	15-32	albumin	Homo sapiens	42-55
744263-1	1978	The ability of 8-methoxypsoralen (8-MOP) to bind human serum albumin has been investigated in vitro through equilibrium dialysis and fluorescence quenching.	Methoxsalen	15-32	albumin	Homo sapiens	55-68
744263-1	1978	The ability of 8-methoxypsoralen (8-MOP) to bind human serum albumin has been investigated in vitro through equilibrium dialysis and fluorescence quenching.	Methoxsalen	34-39	albumin	Homo sapiens	55-68
32862473-2	2021	Clinically used psoralen derivatives 8-methoxypsoralen (8-MOP) and 5-methoxypsoralen at physiologically relevant concentrations were able to activate and photosensitize two recombinant thermoTRP (temperature-gated Transient Receptor Potential) ion channels, TRPA1 (Transient Receptor Potential Ankyrin type 1) and TRPV1 (Transient Receptor Potential Vanilloid type 1), which are known to be involved in pain and itch signaling.	Methoxsalen	37-54	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	258-263
305907-1	1978	Both eaq- and .OH have been found to react with 8-methoxypsoralen (8-MOP), giving rate-constants of 1.1 X 10(10) M-1 s-1.	Methoxsalen	48-65	tumor associated calcium signal transducer 2	Homo sapiens	113-120
305907-1	1978	Both eaq- and .OH have been found to react with 8-methoxypsoralen (8-MOP), giving rate-constants of 1.1 X 10(10) M-1 s-1.	Methoxsalen	67-72	tumor associated calcium signal transducer 2	Homo sapiens	113-120
955227-4	1976	On pure G-6-PDH, methoxsalen exhibited a photoprotective action.	Methoxsalen	17-28	hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase	Homo sapiens	8-15
33579030-9	2021	Together, our findings demonstrate that both coumarins improved cognitive functions, but only xanthotoxin significantly enhanced the learning and memory function and reduced the level of acetylcholinesterase in lipopolysaccharide-treated mice.	Methoxsalen	94-105	acetylcholinesterase	Mus musculus	187-207
32862473-2	2021	Clinically used psoralen derivatives 8-methoxypsoralen (8-MOP) and 5-methoxypsoralen at physiologically relevant concentrations were able to activate and photosensitize two recombinant thermoTRP (temperature-gated Transient Receptor Potential) ion channels, TRPA1 (Transient Receptor Potential Ankyrin type 1) and TRPV1 (Transient Receptor Potential Vanilloid type 1), which are known to be involved in pain and itch signaling.	Methoxsalen	56-61	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	258-263
32862473-2	2021	Clinically used psoralen derivatives 8-methoxypsoralen (8-MOP) and 5-methoxypsoralen at physiologically relevant concentrations were able to activate and photosensitize two recombinant thermoTRP (temperature-gated Transient Receptor Potential) ion channels, TRPA1 (Transient Receptor Potential Ankyrin type 1) and TRPV1 (Transient Receptor Potential Vanilloid type 1), which are known to be involved in pain and itch signaling.	Methoxsalen	56-61	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	265-308
336567-1	1977	8-Methoxypsoralen has been shown to act as a radiosensitizer of hypoxic bacterial cells with uvrA, recA and uvrB and/or lexA mutations.	Methoxsalen	0-17	RAD51 recombinase	Homo sapiens	99-103
905349-0	1977	Photosensitizing effects of 8-methoxypsoralen on the skin of hairless mice--I.	Methoxsalen	28-45	lysine demethylase and nuclear receptor corepressor	Mus musculus	61-69
1148244-3	1975	The double mutant (rad2-20rad9-4) demonstrates a higher sensitivity than each of the single mutants, indicating that at least two pathways are involved in the repair of the 8-methoxypsoralen plus 365 nm induced damages.	Methoxsalen	173-190	ssDNA endodeoxyribonuclease RAD2	Saccharomyces cerevisiae S288C	19-23
32862473-2	2021	Clinically used psoralen derivatives 8-methoxypsoralen (8-MOP) and 5-methoxypsoralen at physiologically relevant concentrations were able to activate and photosensitize two recombinant thermoTRP (temperature-gated Transient Receptor Potential) ion channels, TRPA1 (Transient Receptor Potential Ankyrin type 1) and TRPV1 (Transient Receptor Potential Vanilloid type 1), which are known to be involved in pain and itch signaling.	Methoxsalen	37-54	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	265-308
32862473-2	2021	Clinically used psoralen derivatives 8-methoxypsoralen (8-MOP) and 5-methoxypsoralen at physiologically relevant concentrations were able to activate and photosensitize two recombinant thermoTRP (temperature-gated Transient Receptor Potential) ion channels, TRPA1 (Transient Receptor Potential Ankyrin type 1) and TRPV1 (Transient Receptor Potential Vanilloid type 1), which are known to be involved in pain and itch signaling.	Methoxsalen	56-61	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	314-319
32862473-2	2021	Clinically used psoralen derivatives 8-methoxypsoralen (8-MOP) and 5-methoxypsoralen at physiologically relevant concentrations were able to activate and photosensitize two recombinant thermoTRP (temperature-gated Transient Receptor Potential) ion channels, TRPA1 (Transient Receptor Potential Ankyrin type 1) and TRPV1 (Transient Receptor Potential Vanilloid type 1), which are known to be involved in pain and itch signaling.	Methoxsalen	56-61	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	321-366
32862473-2	2021	Clinically used psoralen derivatives 8-methoxypsoralen (8-MOP) and 5-methoxypsoralen at physiologically relevant concentrations were able to activate and photosensitize two recombinant thermoTRP (temperature-gated Transient Receptor Potential) ion channels, TRPA1 (Transient Receptor Potential Ankyrin type 1) and TRPV1 (Transient Receptor Potential Vanilloid type 1), which are known to be involved in pain and itch signaling.	Methoxsalen	37-54	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	314-319
32862473-2	2021	Clinically used psoralen derivatives 8-methoxypsoralen (8-MOP) and 5-methoxypsoralen at physiologically relevant concentrations were able to activate and photosensitize two recombinant thermoTRP (temperature-gated Transient Receptor Potential) ion channels, TRPA1 (Transient Receptor Potential Ankyrin type 1) and TRPV1 (Transient Receptor Potential Vanilloid type 1), which are known to be involved in pain and itch signaling.	Methoxsalen	37-54	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	321-366
32726786-10	2020	CONCLUSIONS: This study suggests that XAT induces vasorelaxation through the Akt-eNOS-cGMP pathway by activating the KV channel and inhibiting the L-type Ca2+ channel.	Methoxsalen	38-41	AKT serine/threonine kinase 1	Rattus norvegicus	77-80
32862473-3	2021	8-MOP enhanced reactive oxygen species (ROS) production by UVA light, and the effect of 8-MOP on TRPA1 could be abolished by the antioxidant N-acetyl cysteine and by removal of critical cysteine residues from the N-terminus domain of the channel.	Methoxsalen	88-93	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	97-102
32862473-4	2021	Natively expressed mouse TRPA1 and TRPV1 both contribute to photosensitization of cultured primary afferent neurons by 8-MOP, while direct neuronal activation by this psoralen-derivative is mainly dependent on TRPV1.	Methoxsalen	119-124	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	25-30
32862473-4	2021	Natively expressed mouse TRPA1 and TRPV1 both contribute to photosensitization of cultured primary afferent neurons by 8-MOP, while direct neuronal activation by this psoralen-derivative is mainly dependent on TRPV1.	Methoxsalen	119-124	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	35-40
32862473-5	2021	Both TRPA1 and TRPV1 are to a large extent involved in controlling 8-MOP-induced neuropeptide release from mouse trachea.	Methoxsalen	67-72	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	5-10
32862473-5	2021	Both TRPA1 and TRPV1 are to a large extent involved in controlling 8-MOP-induced neuropeptide release from mouse trachea.	Methoxsalen	67-72	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	15-20
32250498-0	2020	Xanthotoxin and umbelliferone attenuate cognitive dysfunction in a streptozotocin-induced rat model of sporadic Alzheimer"s disease: The role of JAK2/STAT3 and Nrf2/HO-1 signalling pathway modulation.	Methoxsalen	0-11	heme oxygenase 1	Rattus norvegicus	165-169
32250498-9	2020	Interestingly, xanthotoxin diminished phosphorylated JAK2 and phosphorylated STAT3 protein expression, while umbelliferone markedly replenished nuclear factor erythroid-derived 2-like 2 (Nrf2) and haem oxygenase-1 (HO-1) levels.	Methoxsalen	15-26	Janus kinase 2	Rattus norvegicus	53-57
32250498-9	2020	Interestingly, xanthotoxin diminished phosphorylated JAK2 and phosphorylated STAT3 protein expression, while umbelliferone markedly replenished nuclear factor erythroid-derived 2-like 2 (Nrf2) and haem oxygenase-1 (HO-1) levels.	Methoxsalen	15-26	signal transducer and activator of transcription 3	Rattus norvegicus	77-82
33283118-6	2020	The gut microbial conversion of xanthotoxin (1) and bergapten (2) with the MRG-PMF1 strain resulted in the production of xanthotoxol (7) and bergaptol (8), respectively, due to the methyl aryl ether cleavage by O-methyltransferase.	Methoxsalen	32-43	MAS1 proto-oncogene like, G protein-coupled receptor	Homo sapiens	75-78
33283118-6	2020	The gut microbial conversion of xanthotoxin (1) and bergapten (2) with the MRG-PMF1 strain resulted in the production of xanthotoxol (7) and bergaptol (8), respectively, due to the methyl aryl ether cleavage by O-methyltransferase.	Methoxsalen	32-43	polyamine modulated factor 1	Homo sapiens	79-83
32638713-10	2020	Absorption to 200 mg EVA1 or EVA2 resulted in 8-MOP concentrations of 57% or 32% in water, 91% or 80% in plasma, and 93% or 92% in DIPE/toluene, while 200 mg PVC A and PVC B yielded recovery rates of 26% and 10% in water, 76% and 75% in plasma, and 55% and 30% in DIPE/toluene, respectively.	Methoxsalen	46-51	myelin protein zero like 2	Homo sapiens	21-25
32045698-0	2020	Imbalanced insulin substrate-1 and insulin substrate-2 signaling trigger hepatic steatosis in vitamin D deficient rats: 8-methoxypsoralen, a vitamin D receptor ligand with a promising anti-steatotic action.	Methoxsalen	120-137	insulin	Homo sapiens	11-18
32045698-0	2020	Imbalanced insulin substrate-1 and insulin substrate-2 signaling trigger hepatic steatosis in vitamin D deficient rats: 8-methoxypsoralen, a vitamin D receptor ligand with a promising anti-steatotic action.	Methoxsalen	120-137	vitamin D receptor	Rattus norvegicus	141-159
32045698-7	2020	Treatment with VD or 8-MOP attenuated IRS1 signaling and its downstream targets, leading to a decline in de novo lipogenesis, while the elevation in IRS2 expression resulted in the nuclear exclusion of forkhead box O1 (FoxO1) and diminished gluconeogenesis, a vital source of acetyl-CoA for de novo lipogenesis.	Methoxsalen	21-26	insulin receptor substrate 1	Rattus norvegicus	38-42
32045698-8	2020	Moreover, 8-MOP and Calcipotriol modulated insulin signaling in human hepatocyte cell line L02, which highlighted the crucial role of VD in the regulation of hepatic lipid contents in rats and humans.	Methoxsalen	10-15	insulin	Homo sapiens	43-50
32045698-9	2020	Silencing of the vitamin D receptor expression in L02 diminished the inhibitory effect of Calcipotriol and 8-MOP on fatty acid synthase and acetyl- CoA carboxylase 1 and provided the evidence that 8-MOP actions mediated via vitamin D receptor.	Methoxsalen	107-112	vitamin D receptor	Homo sapiens	17-35
32045698-9	2020	Silencing of the vitamin D receptor expression in L02 diminished the inhibitory effect of Calcipotriol and 8-MOP on fatty acid synthase and acetyl- CoA carboxylase 1 and provided the evidence that 8-MOP actions mediated via vitamin D receptor.	Methoxsalen	107-112	fatty acid synthase	Rattus norvegicus	116-135
32045698-9	2020	Silencing of the vitamin D receptor expression in L02 diminished the inhibitory effect of Calcipotriol and 8-MOP on fatty acid synthase and acetyl- CoA carboxylase 1 and provided the evidence that 8-MOP actions mediated via vitamin D receptor.	Methoxsalen	107-112	acetyl-CoA carboxylase alpha	Rattus norvegicus	140-165
32045698-9	2020	Silencing of the vitamin D receptor expression in L02 diminished the inhibitory effect of Calcipotriol and 8-MOP on fatty acid synthase and acetyl- CoA carboxylase 1 and provided the evidence that 8-MOP actions mediated via vitamin D receptor.	Methoxsalen	107-112	vitamin D receptor	Homo sapiens	224-242
32045698-9	2020	Silencing of the vitamin D receptor expression in L02 diminished the inhibitory effect of Calcipotriol and 8-MOP on fatty acid synthase and acetyl- CoA carboxylase 1 and provided the evidence that 8-MOP actions mediated via vitamin D receptor.	Methoxsalen	197-202	vitamin D receptor	Homo sapiens	17-35
32045698-9	2020	Silencing of the vitamin D receptor expression in L02 diminished the inhibitory effect of Calcipotriol and 8-MOP on fatty acid synthase and acetyl- CoA carboxylase 1 and provided the evidence that 8-MOP actions mediated via vitamin D receptor.	Methoxsalen	197-202	fatty acid synthase	Rattus norvegicus	116-135
32045698-9	2020	Silencing of the vitamin D receptor expression in L02 diminished the inhibitory effect of Calcipotriol and 8-MOP on fatty acid synthase and acetyl- CoA carboxylase 1 and provided the evidence that 8-MOP actions mediated via vitamin D receptor.	Methoxsalen	197-202	vitamin D receptor	Homo sapiens	224-242
32726786-10	2020	CONCLUSIONS: This study suggests that XAT induces vasorelaxation through the Akt-eNOS-cGMP pathway by activating the KV channel and inhibiting the L-type Ca2+ channel.	Methoxsalen	38-41	nitric oxide synthase 3	Rattus norvegicus	81-85
30577285-0	2018	Infusion of Lymphocytes Treated With 8-Methoxypsoralen and Ultraviolet A Light Induces CD19+IL-10+ Regulatory B Cells and Promotes Skin Allograft Survival.	Methoxsalen	37-54	CD19 antigen	Mus musculus	87-91
29382249-2	2019	The reversible inhibition of methoxsalen and ABT against the P450, FMO, AO, MAO-A and -B, enzymes were evaluated using standard marker probe reactions.	Methoxsalen	29-40	monoamine oxidase A	Homo sapiens	76-88
29382249-6	2019	Methoxsalen is a direct inhibitor and inhibited the activities (>90%) of all enzymes at a concentration of 300 microM except for CYP2C9.	Methoxsalen	0-11	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	132-138
29382249-7	2019	Methoxsalen is also a potent time-dependent inhibitor of all P450 enzymes except for CYP2C19 (moderate) at a concentration of 300 microM.	Methoxsalen	0-11	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	85-92
31313848-8	2019	qRT-PCR analysis revealed that the messenger RNA expression of inflammatory cytokines and chemokine (interleukin-1beta [IL-1beta], IL-6, tumor necrosis factor-alpha, and IL-8) was suppressed by 8-MOP in LPS-stimulated BMECs.	Methoxsalen	194-199	interleukin 1 beta	Bos taurus	101-118
31313848-8	2019	qRT-PCR analysis revealed that the messenger RNA expression of inflammatory cytokines and chemokine (interleukin-1beta [IL-1beta], IL-6, tumor necrosis factor-alpha, and IL-8) was suppressed by 8-MOP in LPS-stimulated BMECs.	Methoxsalen	194-199	interleukin 1 beta	Bos taurus	120-128
31313848-8	2019	qRT-PCR analysis revealed that the messenger RNA expression of inflammatory cytokines and chemokine (interleukin-1beta [IL-1beta], IL-6, tumor necrosis factor-alpha, and IL-8) was suppressed by 8-MOP in LPS-stimulated BMECs.	Methoxsalen	194-199	interferon beta-2	Bos taurus	131-164
31313848-8	2019	qRT-PCR analysis revealed that the messenger RNA expression of inflammatory cytokines and chemokine (interleukin-1beta [IL-1beta], IL-6, tumor necrosis factor-alpha, and IL-8) was suppressed by 8-MOP in LPS-stimulated BMECs.	Methoxsalen	194-199	C-X-C motif chemokine ligand 8	Bos taurus	170-174
31203411-9	2019	However, cell pretreatment with 8-methoxypsoralen (0.1-1 microM), a potent inhibitor of CYP2A, resulted in a 90% decrease of 4-ABP DNA adducts levels.	Methoxsalen	32-49	cytochrome P450 family 2 subfamily A member 13	Homo sapiens	88-93
31203411-9	2019	However, cell pretreatment with 8-methoxypsoralen (0.1-1 microM), a potent inhibitor of CYP2A, resulted in a 90% decrease of 4-ABP DNA adducts levels.	Methoxsalen	32-49	auxin-binding protein T92	Nicotiana tabacum	127-130
30875838-3	2019	Bone mineral density (BMD) and microarchitecture quality were significantly reduced in the diabetic control group; however, both bergapten and methoxsalen reversed serum osteocalcin, bone-alkaline phosphatase and femur BMD.	Methoxsalen	143-154	bone gamma-carboxyglutamate protein 2	Mus musculus	170-181
30419252-3	2019	But those patients receiving PUVA for psoriasis showed an increase in serum 25(OH)D levels, probably highlighting that the vitamin D-vitamin D nuclear receptor (VD-VDR) axis play a protective role in 8-MOP-induced hepatotoxicity.	Methoxsalen	200-205	vitamin D receptor	Homo sapiens	164-167
30419252-6	2019	We proved that 8-MOP could be a potent ligand for VDR using molecular docking and luciferase report assay.	Methoxsalen	15-20	vitamin D receptor	Homo sapiens	50-53
30419252-7	2019	Effect of 8-MOP on VDR subcellular distribution was determined using human liver cell line L02.	Methoxsalen	10-15	vitamin D receptor	Homo sapiens	19-22
30419252-10	2019	The results showed 8-MOP could affect the CYP7A1, SHP and MRP3 expression via VDR, and such effects could be reversed by knockdown of VDR expression, suggesting a vital role of VDR involved in 8-MOP-regulated bile acid synthesis and transportation.	Methoxsalen	19-24	cytochrome P450 family 7 subfamily A member 1	Homo sapiens	42-48
30419252-10	2019	The results showed 8-MOP could affect the CYP7A1, SHP and MRP3 expression via VDR, and such effects could be reversed by knockdown of VDR expression, suggesting a vital role of VDR involved in 8-MOP-regulated bile acid synthesis and transportation.	Methoxsalen	19-24	nuclear receptor subfamily 0 group B member 2	Homo sapiens	50-53
30419252-10	2019	The results showed 8-MOP could affect the CYP7A1, SHP and MRP3 expression via VDR, and such effects could be reversed by knockdown of VDR expression, suggesting a vital role of VDR involved in 8-MOP-regulated bile acid synthesis and transportation.	Methoxsalen	19-24	ATP binding cassette subfamily C member 3	Homo sapiens	58-62
30419252-10	2019	The results showed 8-MOP could affect the CYP7A1, SHP and MRP3 expression via VDR, and such effects could be reversed by knockdown of VDR expression, suggesting a vital role of VDR involved in 8-MOP-regulated bile acid synthesis and transportation.	Methoxsalen	19-24	vitamin D receptor	Homo sapiens	78-81
30419252-10	2019	The results showed 8-MOP could affect the CYP7A1, SHP and MRP3 expression via VDR, and such effects could be reversed by knockdown of VDR expression, suggesting a vital role of VDR involved in 8-MOP-regulated bile acid synthesis and transportation.	Methoxsalen	19-24	vitamin D receptor	Homo sapiens	134-137
30419252-10	2019	The results showed 8-MOP could affect the CYP7A1, SHP and MRP3 expression via VDR, and such effects could be reversed by knockdown of VDR expression, suggesting a vital role of VDR involved in 8-MOP-regulated bile acid synthesis and transportation.	Methoxsalen	19-24	vitamin D receptor	Homo sapiens	134-137
30419252-10	2019	The results showed 8-MOP could affect the CYP7A1, SHP and MRP3 expression via VDR, and such effects could be reversed by knockdown of VDR expression, suggesting a vital role of VDR involved in 8-MOP-regulated bile acid synthesis and transportation.	Methoxsalen	193-198	nuclear receptor subfamily 0 group B member 2	Homo sapiens	50-53
30419252-10	2019	The results showed 8-MOP could affect the CYP7A1, SHP and MRP3 expression via VDR, and such effects could be reversed by knockdown of VDR expression, suggesting a vital role of VDR involved in 8-MOP-regulated bile acid synthesis and transportation.	Methoxsalen	193-198	ATP binding cassette subfamily C member 3	Homo sapiens	58-62
30419252-10	2019	The results showed 8-MOP could affect the CYP7A1, SHP and MRP3 expression via VDR, and such effects could be reversed by knockdown of VDR expression, suggesting a vital role of VDR involved in 8-MOP-regulated bile acid synthesis and transportation.	Methoxsalen	193-198	vitamin D receptor	Homo sapiens	134-137
30419252-10	2019	The results showed 8-MOP could affect the CYP7A1, SHP and MRP3 expression via VDR, and such effects could be reversed by knockdown of VDR expression, suggesting a vital role of VDR involved in 8-MOP-regulated bile acid synthesis and transportation.	Methoxsalen	193-198	vitamin D receptor	Homo sapiens	134-137
30577285-0	2018	Infusion of Lymphocytes Treated With 8-Methoxypsoralen and Ultraviolet A Light Induces CD19+IL-10+ Regulatory B Cells and Promotes Skin Allograft Survival.	Methoxsalen	37-54	interleukin 10	Mus musculus	92-97
30024618-0	2018	Protective effects of 8-MOP on blood-brain barrier via the Nrf-2/HO-1 pathway in mice model of cerebral infarction.	Methoxsalen	22-27	nuclear factor, erythroid derived 2, like 2	Mus musculus	59-64
29764863-8	2018	As in clinical ECP, immunogenic cell death of tumor cells was finely titrated by DNA cross-linkage mediated by photoactivated 8-methoxypsoralen (8-MOPA).	Methoxsalen	126-143	mediator complex subunit 12	Mus musculus	147-151
30024618-8	2018	After 8-MOP treatment, the expression of MMP-9 decreased in ischemic brain tissue, whereas the expression of claudin-5, VEGF, and GFAP increased, suggesting that the blood-brain barrier ultrastructure was improved.	Methoxsalen	6-11	matrix metallopeptidase 9	Mus musculus	41-46
30024618-8	2018	After 8-MOP treatment, the expression of MMP-9 decreased in ischemic brain tissue, whereas the expression of claudin-5, VEGF, and GFAP increased, suggesting that the blood-brain barrier ultrastructure was improved.	Methoxsalen	6-11	claudin 5	Mus musculus	109-118
30024618-8	2018	After 8-MOP treatment, the expression of MMP-9 decreased in ischemic brain tissue, whereas the expression of claudin-5, VEGF, and GFAP increased, suggesting that the blood-brain barrier ultrastructure was improved.	Methoxsalen	6-11	vascular endothelial growth factor A	Mus musculus	120-124
30024618-8	2018	After 8-MOP treatment, the expression of MMP-9 decreased in ischemic brain tissue, whereas the expression of claudin-5, VEGF, and GFAP increased, suggesting that the blood-brain barrier ultrastructure was improved.	Methoxsalen	6-11	glial fibrillary acidic protein	Mus musculus	130-134
30024618-10	2018	However, the expression of Nrf-2 and HO-1 increased in ischemic brain tissue after 8-MOP treatment.	Methoxsalen	83-88	nuclear factor, erythroid derived 2, like 2	Mus musculus	27-32
30024618-11	2018	CONCLUSIONS: 8-MOP may protect the blood-brain barrier via the Nrf-2/HO-1 pathway.	Methoxsalen	13-18	nuclear factor, erythroid derived 2, like 2	Mus musculus	63-68
28677757-0	2017	Hypertrophic differentiation of mesenchymal stem cells is suppressed by xanthotoxin via the p38-MAPK/HDAC4 pathway.	Methoxsalen	72-83	mitogen-activated protein kinase 14	Homo sapiens	92-95
29079042-0	2017	ABC-transporter blockage mediated by xanthotoxin and bergapten is the major pathway for chemosensitization of multidrug-resistant cancer cells.	Methoxsalen	37-48	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	0-15
28677757-0	2017	Hypertrophic differentiation of mesenchymal stem cells is suppressed by xanthotoxin via the p38-MAPK/HDAC4 pathway.	Methoxsalen	72-83	histone deacetylase 4	Homo sapiens	101-106
28550731-0	2017	Xanthotoxin suppresses LPS-induced expression of iNOS, COX-2, TNF-alpha, and IL-6 via AP-1, NF-kappaB, and JAK-STAT inactivation in RAW 264.7 macrophages.	Methoxsalen	0-11	nitric oxide synthase 2	Homo sapiens	49-53
28550731-0	2017	Xanthotoxin suppresses LPS-induced expression of iNOS, COX-2, TNF-alpha, and IL-6 via AP-1, NF-kappaB, and JAK-STAT inactivation in RAW 264.7 macrophages.	Methoxsalen	0-11	prostaglandin-endoperoxide synthase 2	Homo sapiens	55-60
28550731-5	2017	At a molecular level, the effects were related to xanthotoxin-mediated attenuation of the LPS-induced transcriptional and DNA-binding activity of activator protein-1 (AP-1).	Methoxsalen	50-61	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	146-165
28550731-0	2017	Xanthotoxin suppresses LPS-induced expression of iNOS, COX-2, TNF-alpha, and IL-6 via AP-1, NF-kappaB, and JAK-STAT inactivation in RAW 264.7 macrophages.	Methoxsalen	0-11	tumor necrosis factor	Homo sapiens	62-71
28550731-5	2017	At a molecular level, the effects were related to xanthotoxin-mediated attenuation of the LPS-induced transcriptional and DNA-binding activity of activator protein-1 (AP-1).	Methoxsalen	50-61	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	167-171
28550731-0	2017	Xanthotoxin suppresses LPS-induced expression of iNOS, COX-2, TNF-alpha, and IL-6 via AP-1, NF-kappaB, and JAK-STAT inactivation in RAW 264.7 macrophages.	Methoxsalen	0-11	interleukin 6	Homo sapiens	77-81
28550731-0	2017	Xanthotoxin suppresses LPS-induced expression of iNOS, COX-2, TNF-alpha, and IL-6 via AP-1, NF-kappaB, and JAK-STAT inactivation in RAW 264.7 macrophages.	Methoxsalen	0-11	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	86-90
28550731-7	2017	Xanthotoxin also displayed a suppressive effect on the transcriptional and DNA-binding activity of nuclear transcription factor kappa-B (NF-kappaB) by inhibiting p65 nuclear translocation.	Methoxsalen	0-11	nuclear factor kappa B subunit 1	Homo sapiens	128-135
28550731-7	2017	Xanthotoxin also displayed a suppressive effect on the transcriptional and DNA-binding activity of nuclear transcription factor kappa-B (NF-kappaB) by inhibiting p65 nuclear translocation.	Methoxsalen	0-11	nuclear factor kappa B subunit 1	Homo sapiens	137-146
28550731-0	2017	Xanthotoxin suppresses LPS-induced expression of iNOS, COX-2, TNF-alpha, and IL-6 via AP-1, NF-kappaB, and JAK-STAT inactivation in RAW 264.7 macrophages.	Methoxsalen	0-11	nuclear factor kappa B subunit 1	Homo sapiens	92-101
28550731-7	2017	Xanthotoxin also displayed a suppressive effect on the transcriptional and DNA-binding activity of nuclear transcription factor kappa-B (NF-kappaB) by inhibiting p65 nuclear translocation.	Methoxsalen	0-11	RELA proto-oncogene, NF-kB subunit	Homo sapiens	162-165
28550731-3	2017	Xanthotoxin inhibited production of nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor (TNF-alpha), and interleukin-6 (IL-6) by the LPS-induced macrophages in a concentration-dependent manner.	Methoxsalen	0-11	tumor necrosis factor	Homo sapiens	80-101
28550731-8	2017	In addition, xanthotoxin significantly reduced the phosphorylation at signal transducers and activators of transcription 1 (STAT1, Ser 727 and Tyr 701) and STAT3 (Tyr 705), as well as Janus kinase (JAK) 1 and 2 in LPS-induced RAW 264.7 macrophages.	Methoxsalen	13-24	signal transducer and activator of transcription 1	Homo sapiens	70-122
28550731-8	2017	In addition, xanthotoxin significantly reduced the phosphorylation at signal transducers and activators of transcription 1 (STAT1, Ser 727 and Tyr 701) and STAT3 (Tyr 705), as well as Janus kinase (JAK) 1 and 2 in LPS-induced RAW 264.7 macrophages.	Methoxsalen	13-24	signal transducer and activator of transcription 1	Homo sapiens	124-129
28550731-3	2017	Xanthotoxin inhibited production of nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor (TNF-alpha), and interleukin-6 (IL-6) by the LPS-induced macrophages in a concentration-dependent manner.	Methoxsalen	0-11	tumor necrosis factor	Homo sapiens	103-112
28550731-8	2017	In addition, xanthotoxin significantly reduced the phosphorylation at signal transducers and activators of transcription 1 (STAT1, Ser 727 and Tyr 701) and STAT3 (Tyr 705), as well as Janus kinase (JAK) 1 and 2 in LPS-induced RAW 264.7 macrophages.	Methoxsalen	13-24	signal transducer and activator of transcription 3	Homo sapiens	156-161
28550731-3	2017	Xanthotoxin inhibited production of nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor (TNF-alpha), and interleukin-6 (IL-6) by the LPS-induced macrophages in a concentration-dependent manner.	Methoxsalen	0-11	interleukin 6	Homo sapiens	119-132
28550731-8	2017	In addition, xanthotoxin significantly reduced the phosphorylation at signal transducers and activators of transcription 1 (STAT1, Ser 727 and Tyr 701) and STAT3 (Tyr 705), as well as Janus kinase (JAK) 1 and 2 in LPS-induced RAW 264.7 macrophages.	Methoxsalen	13-24	Janus kinase 1	Homo sapiens	184-210
28550731-3	2017	Xanthotoxin inhibited production of nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor (TNF-alpha), and interleukin-6 (IL-6) by the LPS-induced macrophages in a concentration-dependent manner.	Methoxsalen	0-11	interleukin 6	Homo sapiens	134-138
28550731-9	2017	Finally, xanthotoxin suppressed the LPS-induced phosphorylation of extracellular signal-regulated kinase (ERK) 1/2 and p38 mitogen-activated protein kinase (MAPK).	Methoxsalen	9-20	mitogen-activated protein kinase 3	Homo sapiens	67-114
28627461-0	2017	8-methoxypsoralen reduces AKT phosphorylation, induces intrinsic and extrinsic apoptotic pathways, and suppresses cell growth of SK-N-AS neuroblastoma and SW620 metastatic colon cancer cells.	Methoxsalen	0-17	AKT serine/threonine kinase 1	Homo sapiens	26-29
28550731-9	2017	Finally, xanthotoxin suppressed the LPS-induced phosphorylation of extracellular signal-regulated kinase (ERK) 1/2 and p38 mitogen-activated protein kinase (MAPK).	Methoxsalen	9-20	mitogen-activated protein kinase 14	Homo sapiens	119-155
28550731-9	2017	Finally, xanthotoxin suppressed the LPS-induced phosphorylation of extracellular signal-regulated kinase (ERK) 1/2 and p38 mitogen-activated protein kinase (MAPK).	Methoxsalen	9-20	mitogen-activated protein kinase 3	Homo sapiens	157-161
28550731-10	2017	Taken together, these results indicate that xanthotoxin decreases NO, PGE2, TNF-alpha, and IL-6 production by downregulation of the NF-kappaB, AP-1, and JAK/STAT signaling pathways in LPS-induced RAW 264.7 macrophages.	Methoxsalen	44-55	tumor necrosis factor	Homo sapiens	76-85
28550731-10	2017	Taken together, these results indicate that xanthotoxin decreases NO, PGE2, TNF-alpha, and IL-6 production by downregulation of the NF-kappaB, AP-1, and JAK/STAT signaling pathways in LPS-induced RAW 264.7 macrophages.	Methoxsalen	44-55	interleukin 6	Homo sapiens	91-95
28550731-10	2017	Taken together, these results indicate that xanthotoxin decreases NO, PGE2, TNF-alpha, and IL-6 production by downregulation of the NF-kappaB, AP-1, and JAK/STAT signaling pathways in LPS-induced RAW 264.7 macrophages.	Methoxsalen	44-55	nuclear factor kappa B subunit 1	Homo sapiens	132-141
28550731-10	2017	Taken together, these results indicate that xanthotoxin decreases NO, PGE2, TNF-alpha, and IL-6 production by downregulation of the NF-kappaB, AP-1, and JAK/STAT signaling pathways in LPS-induced RAW 264.7 macrophages.	Methoxsalen	44-55	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	143-147
28627461-14	2017	8-MOP reduced the phosphorylation of AKT308, decreased the expression of Bcl-2, increased the Bax protein level, and activated caspases -8, -9, and -3 in both cell lines.	Methoxsalen	0-5	BCL2 apoptosis regulator	Homo sapiens	73-78
28627461-14	2017	8-MOP reduced the phosphorylation of AKT308, decreased the expression of Bcl-2, increased the Bax protein level, and activated caspases -8, -9, and -3 in both cell lines.	Methoxsalen	0-5	BCL2 associated X, apoptosis regulator	Homo sapiens	94-97
28627461-14	2017	8-MOP reduced the phosphorylation of AKT308, decreased the expression of Bcl-2, increased the Bax protein level, and activated caspases -8, -9, and -3 in both cell lines.	Methoxsalen	0-5	caspase 8	Homo sapiens	127-150
28552422-0	2017	8-Methoxypsoralen disrupts MDR3-mediated phospholipids efflux and bile acid homeostasis and its relevance to hepatotoxicity.	Methoxsalen	0-17	ATP binding cassette subfamily B member 4	Homo sapiens	27-31
28552422-12	2017	Our investigation represent the first evidence that 8-MOP can induce cholestatic liver injury by disturbing MDR3-mediated phospholipids efflux and bile acid homeostasis.	Methoxsalen	52-57	ATP binding cassette subfamily B member 4	Homo sapiens	108-112
28629211-9	2017	Methoxsalen was cytotoxic at 300-700 muM in a concentration-dependentfashion.	Methoxsalen	0-11	latexin	Homo sapiens	37-40